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1.1. Research background  
 
Working equids (horses, mules, and donkeys) have a great significance in the development of 
Ethiopia, where they have an essential role in reducing poverty, providing food security, and 
enhancing rural development. These equids perform numerous activities on a daily basis, 
including the transportation of goods, people, and construction materials, as well as being used 
in agricultural and tourism activities. The United Nation Food and Agriculture Organization 
estimates that Ethiopia has more than 6 million donkeys, the second largest donkey population 
in the world next to China with 1.9 million horses and over 350, 000 mules (Anonymous, 2010). 
Infectious diseases compromise the health and welfare of working equids, which in turn 
threatens the livelihoods of the most vulnerable members of the society (Stringer et al., 2015). 
However, there are limited or no data quantifying the occurrence, prevalence, and distribution 
of many infectious diseases in working equids in developing countries. In Ethiopia, previous 
studies documented that the major factors that affect the health status and performance of 
working equids includes harness related wounds and sores (Biffa and Woldemeskel, 2006), 
coughing and nasal discharge (Laing et al., 2016), epizootic lymphangitis (Ameni, 2006; 
Scantlebury et al., 2013), African horse sickness (Ayelet et al., 2013; Aklilu et al., 2014), 
strangles (Laing et al., 2016), helminthiasis (Seyoum et al., 2015; Sheferaw and Alemu, 2013), 
and ocular diseases (Scantlebury et al., 2013). These diseases are widely distributed in different 
parts of Ethiopia and cause considerable morbidity and mortality. Until recently, the occurrence 
and distribution of herpesvirus infections in Ethiopian equids had not been known. Since 2009, 
widespread outbreaks, that are suspected of being associated with EHV-1 have been reported. 
Currently, the equine herpesviral infections remain an important cause of serious morbidity and 
mortality in Ethiopian equids.  
 
1.2. Equine herpesviruses 
 
1.2.1. Historical perspective 
 
Equine herpesvirus-1 (EHV-1) was first described by Dimock and Edwards at the Kentucky 
Agricultural Experimental Station, Lexington in the early 1930s after necropsy examination of 
an aborted fetus (Dimock and Edwards, 1933). Major antigenic differences between EHV-1 
strains have been reported as early as 1959, but were not fully differentiated (Studdert et al., 
Chapter 1 
3 
1981). Until 1981, two subtypes of this virus were described; EHV-1 subtype 1 was mainly 
associated with abortion and nervous system disorders and EHV-1 subtype 2 was mainly 
responsible for respiratory disease. Restriction endonuclease fingerprinting subsequently 
demonstrated that these two subtypes were closely related, but genetically distinct viruses and 
therefore, they were reclassified as EHV-1 (formerly subtype 1) and EHV-4 (formerly subtype 
2) (Studdert et al., 1981; O’Callaghan and Osterrieder, 2008). EHV-3, the cause of equine coital 
exanthema (ECE), was first described in Ireland in the early 1900s (Craig and Kehoe, 1921). It 
was first isolated independently in 1968 in the United States, Canada, and Australia (Bryans, 
1968; Girard et al., 1968; Pascoe et al., 1968) and has a worldwide distribution. EHV-2 was 
first isolated from a horse with upper respiratory tract disease in 1963 (Plummer and Waterson, 
1963; Plummer et al., 1969). In 1987, EHV-5 was recognized for the first time from a large 
viral collection using restriction endonuclease analysis (Browning and Studdert, 1987a).  
 
1.2.2. Taxonomy 
 
Following the recommendations of the Herpesviridae study group, the International Committee 
on Taxonomy of Viruses (ICTV) has summarized herpesviruses within a new order, 
Herpesvirales, which is categorized into three families: the Herpesviridae, the 
Alloherpesviridae, and the Malacoherpesviridae (Davison, 2010; King et al., 2012). The order 
has more than 100 members with a wide spectrum of hosts, ranging from humans and other 
mammals to birds, amphibians, reptiles, and invertebrates (Lacoste et al., 2010). The 
Herpesviridae family contains mammal, reptile, and avian viruses; the Alloherpesviridae 
family contains fish and amphibian viruses and the Malacoherpesviridae family contains only 
the invertebrate bivalve mollusk virus (Davison et al., 2009). The Herpesviridae family has a 
broad range of pathogens that have been grouped into the subfamilies Alpha-, Beta-, and 
Gammaherpesvirinae based on host range, duration of the reproductive cycle, cytopathology, 
and characteristic of latent infection (Roizman and Baines, 1991). 
 
The subfamily Alphaherpesvirinae has a variable host range, relatively short reproductive 
cycle, rapid growth in culture, efficient destruction of infected cells, and capacity to establish 
latent infections (Roizman and Baines, 1991). This subfamily has five genera: Iltovirus, 
Mardivirus, Scutavirus, Simplexvirus, and Varicellovirus (King et al., 2012). The EHV-1, -3, 
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and -4 are members of the Alphaherpesvirinae subfamily and belong, along with bovine 
herpesvirus-1, suid herpesvirus-1, canine herpesvirus-1, felid herpesvirus-1, and Marek’s 
disease virus, and the prototypic virus of the human pathogen varicella-zoster virus, to the genus 
Varicellovirus (King et al., 2012; Davison, 2014). Other equine viruses belonging to this genus 
are EHV-6 (asinine herpesvirus 1), EHV-8 (asinine herpesvirus 3) and EHV-9 (gazelle 
herpesvirus) (Table 1). 
 
In contrast, the subfamily Betaherpesvirinae has a restricted host range, long reproductive 
cycle, and the infection progresses slowly in culture. The infected cells frequently become 
enlarged (cytomegaly) (Roizman and Baines, 1991). Four genera are present within the 
subfamily Betaherpesvirinae: Cytomegalovirus, Muromegalovirus, Proboscivirus, and 
Roseolovirus (Davison et al., 2009; King et al., 2012). Initially, EHV-2 and EHV-5 were 
classified in the Betaherpesvirinae subfamily (Roizman and Baines, 1991). However, Telford 
et al. (1993) demonstrated that the nucleotide sequence of 39 kbp of EHV-2 and 42 kbp of 
EHV-5 genome shared greater degree of homology with the gammaherpesviruses Epstein-Barr 
virus and herpesvirus saimiri than with any other herpesviruses, and therefore, they were 
reclassified in the Gammaherpesvirinae subfamily. 
 
The subfamily Gammaherpesvirinae comprises viruses that are host-specific in vitro, and have 
a slow growth rate and a high degree of cell-association. This subfamily encompasses the genus 
Lymphocryptovirus, Macavirus, Percavirus, and Rhadinovirus. Initially, EHV-2 and EHV-5 
were classified in the Rhadinovirus sub-family of the Gammaherpesvirinae. However, more 
recently, they were reclassified in the genus Percavirus (Ackermann, 2006; Davison, 2002; 
Davison et al., 2009; King et al., 2012). 
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Table 1: The known herpesviruses in equids. 
 
     
Taxon name Common name Sub-
family 
Host Clinical signs 
     
Equid herpesvirus 1 Equine abortion virus α Horse Respiratory disease, abortion, 
myeloencephalopathy, 
chorioretinopathy 
Equid herpesvirus 2 Equine herpesvirus 2  γ Horse Respiratory disease, 
conjunctivitis 
Equid herpesvirus 3 Equine coital 
exanthema virus 
α Horse Coital exanthema 
Equid herpesvirus 4 Equine 
rhinopneumonitis virus 
α Horse Respiratory disease 
Equid herpesvirus 5 Equine herpesvirus 5  γ Horse Respiratory disease, 
multinodular pulmonary fibrosis 
Equid herpesvirus 6 Asinine herpesvirus 1 α Donkey Lesions on the external genitalia 
and udder 
Equid herpesvirus 7 Asinine herpesvirus 2 γ Donkey Not known 
Equid herpesvirus 8 Asinine herpesvirus 3 α Donkey Respiratory disease 
Equid herpesvirus 9 Gazelle herpesvirus α Gazelle  Respiratory disease, encephalitis  
Asinine herpesvirus 4 Asinine herpesvirus 4 γ Donkey Pneumonia 
Asinine herpesvirus 5 Asinine herpesvirus 5 γ Donkey Pneumonia 
Asinine herpesvirus 6 Asinine herpesvirus 6 γ Donkey Pneumonia 
Zebra herpesvirus Zebra herpesvirus γ Zebra Pneumonia 
Wild ass herpesvirus Wild ass herpesvirus γ Wild ass Pneumonia 
 
The known herpesviruses appear to share the following significant biological properties 
(Roizman and Baines, 1991): (1) all herpesviruses specify a large array of enzymes involved in 
the processing of proteins and in nucleic acid metabolism. Although all herpesviruses specify 
a DNA polymerase and other proteins involved in DNA synthesis, the exact array of enzymes 
may vary from one herpesvirus to another; (2) the synthesis of viral DNAs and assembly of 
capsids occur in the nucleus, acquire an envelope by budding through the nuclear membrane; 
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(3) production of infectious progeny virus is invariably accompanied by the irreversible 
destruction of the infected cell; (4) latency is established in their natural hosts. 
 
1.2.3. General structure 
 
The architecture of the member of the family Herpesviridae differs significantly with respect 
to the properties of their DNAs, gene content, and linear arrangement of the genes in viral 
genomes (Roizman and Baines, 1991). A typical herpesvirion consists of a core containing a 
linear double stranded DNA, icosahedral capsid surrounded by a structured tegument, and an 
envelope containing viral glycoprotein spikes on its surface (Figure 1). 
 
 
Figure 1: Schematic representation (A) and electron photomicrograph (B) of the morphology 
of an equine herpesvirus (adapted from Paillot et al., 2008). 
 
Viral genome: EHV-1, -3, and -4 possess linear double-stranded DNA genomes and share the 
same overall genome conformation with a unique long region (UL) linked to a unique short 
region (US) that is flanked by an identical pair of inverted repeat regions, the terminal repeat 
(TR) and internal repeat (IR) regions (Telford et al., 1992, 1998; O’Callaghan and Osterrieder, 
2008). The EHV-1, -3, and -4 genomes are 150 kbp, 151 kbp, and 146 kbp in length, 
respectively. All encode 76 homologous genes, with three duplicated genes in EHV-4 and four 
duplicated genes in EHV-1 and EHV-3 within the repeat regions (Telford et al., 1992, 1998; 
Sijmons et al., 2014). EHV-1 and EHV-4 are antigenically very closely related. They exhibit 
55 - 84% nucleotide sequence homology and the antibodies can cross-neutralize. EHV-3 is the 
B A 
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most divergent of the equine alphaherpesviruses with an overall nucleotide sequence homology 
with the other viruses ranging from 62.1 - 64.9% (Sijmons et al., 2014).  
 
EHV-2 and EHV-5 are distinct, but closely related equid herpesviruses, sharing approximately 
60% nucleotide sequence homology at the nucleotide and amino acid levels (O’Callaghan and 
Osterrieder, 2008; Fortier et al., 2010). The genome of EHV-2 is a 184 kbp double-stranded 
DNA genome and has 79 open reading frame (ORF) encoding 77 distinct proteins (Telford et 
al., 1995). The unique region of EHV-2 contains an unrelated pair of internal, short inverted 
repeats at separate locations. In contrast, the EHV-5 genome is 179 kbp in size and lacks both 
the terminal and the internal sequence repeats (Allen and Murray, 2004) (Figure 2). 
  
 
 
 
 
 
Figure 2: The genome structure of EHVs. Each linear genomic DNA is shown with unique 
sequences as horizontal lines and repeats as boxes. Orientations of repeats are indicated by 
arrows. The genomes of EHV-1, -3 and -4 contain two unique regions; the unique long region 
(UL) and the unique short region (US). US is flanked by a repeat region creating identical, but 
inverted, repeats: the internal (IR) repeat and terminal repeat (TR) regions. 
 
Capsid: In all herpesviruses, the capsid is an icosahedron and has an external diameter of 125 
- 130 nm. It consists of 162 capsomeres (12 pentons and 150 hexons) each containing five and 
six copies of the major capsid protein, respectively (Roizman and Baines, 1991; Brown and 
Newcomb, 2011).  
 
Tegument: Herpesvirus tegument is a self-supporting structure comprising thousands of 
densely-packaged protein molecules. It occupies the space between the capsid and the envelope 
(Owen et al., 2015).  
3’ 
5’ 
EHV-5 
EHV-2 
EHV-1, -3, -4 
IR 
Us 
TR 
UL 
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Envelope: The envelope is largely derived from the trans-Golgi network of the host cell and 
contains viral glycoproteins (Hudnall et al., 2011). For the equid herpesviruses, most of the 
structural and functional data are available for EHV-1 and EHV-4. The genomes of EHV-1 and 
EHV-4 encode 12 envelope-anchored surface glycoproteins; namely glycoprotein (g) B, gC, 
gD, gE, gG, gH, gI, gK, gL, gM, gN, and gp2, which are involved in virus attachment, cell 
penetration and egress, cell-to-cell spread as well as pathogenicity and virulence (Table 2).  
Moreover, because of their location in the viral envelope and on the surface of infected cells, 
glycoproteins are also prime targets of the host's immune response. The gB, gD, gH, gK, and 
gL are essential glycoproteins which are absolutely required for virus replication in tissue 
culture (O’Callaghan and Osterrieder, 2008; Osterrieder and Van de Walle, 2010). 
 
Table 2. Equine herpesvirus 1 glycoproteins and their functions  
 
Glyco- 
proteins  
Function References 
   
gB Cell penetration and cell-to-cell spread Wellington et al., 1996; Neubauer et al., 1997  
gC Mediates cell attachment and egress Osterrieder, 1999 
gD Cell penetration, cell-to-cell spread, 
cellular tropism and host  cell specificity 
Csellner et al., 2000; Sasaki et al., 2011; 
Azab and Osterrieder, 2012 
gE Cell-to-cell spread and virulence Matsumura et al., 1998; O’Callaghan and 
Osterrieder, 2008 
gG Viral chemokine binding protein Bryant et al., 2003; Van De Walle et al., 2007  
gH Integrin-independent cell-to-cell spread Azab et al., 2012 
gI Cell-to-cell spread and virulence Matsumura et al., 1998; O’Callaghan and 
Osterrieder, 2008 
gK Cell-to-cell spread and virus egress Neubauer and Osterrieder, 2004 
gL Proper folding, intracellular transport, 
and full functionality of gH 
Azab et al., 2012 
gM Cell penetration and cell-to-cell spread Rudolph and Osterrieder, 2002 
gN gM processing Osterrieder et al., 1996 
gp2 Virus egress and major determinant of 
virulence 
Rudolph and Osterrieder, 2002; O’Callaghan 
and Osterrieder, 2008  
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1.2.4. Replication cycle 
 
The alphaherpesvirus replication cycle consists of several steps, including virus entry into the 
host cell, replication inside the host cell, and release of the virus from the host cell. A schematic 
representation of the various steps of the alphaherpesvirus replication cycle is shown in Figure 
3. 
 
 
Figure 3: Replication cycle of the alphaherpesviruses (adapted from Mettenleiter et al., 2009). 
The replication cycle is initiated by the attachment of free virions to the surface of the target 
cells (1). Then, the viral capsid is released into the cytoplasm (2), transported into the nucleus 
(N) (3) via the microtubules (MT) (4), and docking at the nuclear pore (NP) (5) where the viral 
genome is released into the nucleus. In the nucleus, DNA replication and transcription of the 
viral genes occurs (6). The subsequent packaging of these genomes into newly formed capsids 
(7) is known as the encapsidation process (8). The nucleocapsids leave the nucleus via budding 
through the inner nuclear membrane (NM) (9), thereby acquiring their primary envelope, 
followed by fusion of the envelope of these primary virions located in the perinuclear space 
(10) with the outer nuclear membrane (11) resulting in the entry of naked nucleocapsids into 
the cytoplasm. Finally, the nucleocapsids acquire their secondary envelope from the trans-Golgi 
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network (TGN) (12). After transport to the cell surface (13), vesicle and plasma membrane fuse, 
releasing a mature, enveloped virion from the cell (14).   
 
Virus attachment and entry 
Entry of herpesviruses into the target cells is regulated by interactions with a number of cellular 
receptors that mediate the attachment, initiate signaling cascades, or trigger virus internalization 
(Heldwein, 2016). To initiate infection, the virion attaches to cell membranes by the interaction 
of gC and gB to the heparan sulfate moieties of the cell surface proteoglycans (Shieh et al., 
1992; Osterrieder, 1999). The gD is essential for stable binding to cell surface receptors and 
triggers fusion (Spear and Longnecker, 2003; Van de Walle et al., 2008). After initial 
attachment, virus entry occurs either by direct fusion of the virus envelope with the plasma 
membrane in equine dermal cells, endothelial cells, and rabbit kidney cells or via endocytosis 
in CHO-K1 cells and peripheral blood mononuclear cells (PBMCs) following fusion between 
the virus envelope and an endosomal membrane (Neubauer et al., 1997; Van de Walle et al., 
2008). EHV-1 entry via endocytosis is mediated by cellular αV integrins and arginine-serine-
aspartic acid (RSD) motif at amino acid positions 152-154 present in EHV-1 gD (Van de Walle 
et al., 2008). Recently, Kurtz et al. (2010) and Sasaki et al. (2011) demonstrated that Equus 
caballus major histocompatibility complex class I (MHC-I) can be identified as a cellular entry 
receptor for the EHV-1. Subsequently, the de-enveloped virus released into the cytoplasm of 
infected cells, utilizes the microtubule network and the motor protein dynein to move towards 
the nuclear pore of the cell (Frampton et al., 2010). At the nuclear pores, the nucleocapsid 
releases its DNA into the nucleus, leaving an empty capsid behind. Successful EHV-1 infection 
requires the activation of cell signaling molecules, the serine/threonine Rho kinase ROCK1, 
regardless of the mode of initial entry (Frampton et al., 2007). 
 
Genome replication 
Viral DNA replication initiates at approximately 4h post infection and requires the virus-
encoded DNA polymerase (O’Callaghan and Osterrieder, 2008). The transcription of viral 
DNA takes place inside the nucleus, but all viral proteins are synthesized in the cytoplasm. 
DNA replication occurs with sequential transcription and translation of immediate early (IE), 
early (E), and late (L) genes. The first set of viral genes to be transcribed are the IE genes, which 
produce control proteins that stimulate and regulate all the subsequent steps in the replicative 
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cycle. Their production is essential to stimulate the production of E polypeptides, which are the 
enzymes and other proteins involved in viral nucleic acid reproduction. Products of IE and E 
genes transactivate the translation of the L genes, which produce the late proteins, the structural 
proteins for the virion including the viral capsid and glycoproteins (Klapper and Van Loon, 
2010; Slater, 2014). 
 
Virus assembly and egress 
The newly synthesized DNA copies have to assemble with the capsid proteins to form 
nucleocapsids. The host RNA polymerase II transcribes the IE genes; the mRNAs are 
transported into the cytoplasm where translation occurs. The IE proteins activate transcription 
of the E genes that are involved in viral DNA replication. Following viral DNA replication, L 
viral genes start to be transcribed. The L proteins are involved in assembling the capsids within 
the nucleus (Gruffat et al., 2016). The capsid proteins then translocate to the nucleus of the 
infected cell. After intranuclear assembly, nucleocapsids bud at the inner leaflet of the nuclear 
membrane into the perinuclear space, resulting in enveloped particles in the perinuclear space, 
thus acquiring a primary envelope. The primary envelope then fuses with the outer leaflet of 
the nuclear membrane thereby releasing naked nucleocapsids into the cytoplasm (Mettenleiter, 
2004). The naked nucleocapsids acquire their final tegument in the cytoplasm and tegumented 
capsids obtain their final envelope by budding into vesicles of the trans-Golgi network 
(Granzow et al., 2001; Mettenleiter, 2002; Mettenleiter et al., 2006). 
 
1.2.5. Epidemiology  
 
Transmission 
Infection with EHV-1, -2, -4, and -5 occurs through the respiratory tract by inhalation of the 
aerosolized infectious virus, nose-to-nose contact, or contact with fomites (Bell et al., 2006; 
Hussey and Landolt, 2015), whereas EHV-3 is transmitted through direct skin-to-skin contact 
during coitus or through secretions containing live virus (Hussey and Landolt, 2015). The 
presence of EHV-1 in semen of infected stallions has been reported (Hebia-Fellah et al., 2009; 
Fritsche and Borchers, 2011). Hebia-Fellah et al. (2009) demonstrated EHV-1 DNA in 13% 
(51/390) of semen samples using conventional PCR test. EHV-1 shedding in semen was also 
detected on day 20 after the onset of fever in naturally infected stallions using real-time PCR 
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(Walter et al., 2012). Tearle et al. (1996) recovered EHV-1 from the epididymis and the testis 
in an experimental study. Although EHV-1 can replicate in the testes and epididymis and be 
shed in the semen, it is still unclear whether the virus can actually spread by the venereal route. 
 
Host 
EHVs circulate in a given horse population via silent or clinical infections or reactivation of 
latent infections. The horse is the natural host to EHV-1, -2, -3, -4 and -5. Although all breeds 
of horses are susceptible to EHV-1 infection, clinically EHV-1-affected donkeys and mules 
have not been reported in previous studies. However, donkeys and mules have shown 
seroconversion indicating infection with EHV-1 while in contact with affected horses during 
outbreaks (Pusterla et al., 2012). Although horses and mules are both exposed to EHV-1 during 
equine herpesvirus myeloencephalopathy (EHM) outbreaks, the clinical neurological signs 
have only been seen in horses (Pusterla et al., 2012). Mules and donkeys are serve as reservoirs 
and potential silent shedders of EHV-1 during an outbreak of EHV-1 (Van Maanen, 2002; 
Pusterla et al., 2012). EHV-1 can occasionally infect non-equid species including llamas (Lama 
glama), alpacas (Vicugna pacos), blackbuck (Antelopa cervicapra), black bears (Ursus 
americanus), Thomson’s gazelles (Eudorcas thomsoni), and guinea pigs (Cavia porcellus) 
(Chowdhury et al., 1988; Rebhun et al., 1992; Pagamjav et al., 2007; Wohlsein et al., 2011). 
 
Latency and reactivation 
The epidemiological features of EHV infections are: (i) high incidence of respiratory infection 
early in life with low morbidity, (ii) establishment of lifelong latency in a large proportion of 
infected equids, and (iii) frequent reactivation of latent virus with subsequent shedding, 
resulting in transmission to naive hosts (Edington, 1992, Allen et al., 2004; Hussey and Landolt, 
2015). EHV-1 establishes latency in the lymphoreticular system, both in circulating leukocytes 
and in lymph nodes, and in the trigeminal ganglion. EHV-2 is latent in B-lymphocytes, 
macrophages, and possibly Langerhans cells (Borchers et al., 1997a; Allen and Murray, 2004; 
Drummer et al., 1996). The sites of EHV-4 latency are sensory ganglia (Borchers et al., 1997b) 
and lymphoreticular tissues. In contrast, the anatomical sites that harbor latent EHV-3 (Allen 
and Umphenour, 2004) and EHV-5 (Gilkerson et al., 2015) are unknown. The establishment of 
latency provides a permanent reservoir for the EHVs which makes total disease eradication 
highly unlikely. 
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Periodically, latently infected horses experience reactivation episodes, during which infectious 
virus is shed into respiratory tract secretions, with the potential of infecting other susceptible 
horses (Slater, 2014). The physiological factors responsible for the activation of the latent virus 
are anecdotally associated with stressors including weaning, commingling, transportation, and 
concurrent infections (Lunn et al., 2009). Recrudescence during times of host stress is thought 
to result in anterograde axonal transport of virus to the site of initial infection (Pusterla et al., 
2012). During latency, the entire viral genome is present within the nucleus of the host cells, 
but transcription of viral DNA is limited. This renders the virus invisible to immune 
surveillance (Grinde, 2013).  
 
Prevalence 
Estimates of the prevalence of EHV infections strongly vary with viral detection technologies 
(Lunn et al., 2009). The prevalence of latent EHV-1 infection in horses varies between 54 and 
88% (Edington et al., 1994; Allen et al., 2008; Lunn et al., 2009; Pusterla et al., 2010). Latent 
EHV-2 and EHV-5 infections have been detected in 75 and 88% of  foals, respectively (Bell et 
al., 2006). Information regarding the prevalence of latent EHV-3 is scarce. Barrandeguy et al. 
(2008) demonstrated reactivation of latent EHV-3 after corticosteroid administration. Surveys 
to estimate the seroprevalence of EHV infections have revealed the existence of antibodies in 
most horse populations. The serological surveys of EHV-1 and EHV-4 have always been 
complicated by the presence of antigenic cross-reactivity and the widespread use of EHV-1 
and/or EHV-4 vaccines (Patel and Heldens, 2005). Currently, a type-specific ELISA is 
available, which can distinguish antibodies to EHV-1 and EHV-4 (Crabb et al., 1995). The 
seroprevalence of EHV-1 and EHV-4 in horses has been reported between 8 and 85.2% 
(Gilkerson et al., 1999a; Pusterla et al., 2009) and approximately over 90%, respectively 
(Aharonson-Raz et al., 2014; Gilkerson et al., 1999b). Information associated with the 
prevalence of EHV infections in donkeys and mules is limited. EHV-1 has been reported with 
a seroprevalence of 37.2% (32/86) in mules and 24.2% (31/128) in donkeys using a virus 
neutralization (VN) test in Turkey (Ataseven et al., 2009).  
 
The genome sequence of EHVs has facilitated molecular epidemiological studies. Sequence 
analysis of EHV-1 strains revealed a nucleotide variation rate of approximately 0.1% (Nugent 
et al., 2006; Slater et al., 2006). A region of ORF68 gene of EHV-1 has the highest sequence 
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variation rate (2%) and has been used as a phylogenetic marker to distinguish an international 
collection of viruses into six groups (Nugent et al., 2006). This phylogenetic marker helps to 
trace the source of the EHV-1 disease outbreaks (Barbic et al., 2012), but do not provide any 
relationship between the phylogenetic groups and the paralytic potential of strains (Slater et al., 
2006). The sequence variation of the DNA polymerase gene encoded by ORF30 provides a 
means of identifying paralytic viruses. EHM is significantly associated with a single nucleotide 
polymorphism resulting in an amino acid variation of the EHV-1 DNA polymerase (Nugent et 
al., 2006; Goodman et al., 2007; Van de Walle et al., 2009). EHV-1 encoding aspartic acid 
(D752) has a higher risk of causing neurological disease than EHV-1 with asparagine (N752) at 
amino acid position 752 (Nugent et al., 2006). The EHV-1 N752 variants have been responsible 
for approximately 95 to 98% of abortion outbreaks and between 15 and 25% of neurological 
outbreaks (Lunn et al., 2009). However, recent studies show an increase of the neuropathogenic 
variant of EHV-1 in abortion outbreaks (Smith et al., 2010; Damiani et al., 2014). The 
neuropathogenic variants have a longer duration and greater magnitude of viremia and 
significantly higher number of infected immune cells when compared to non-neuropathogenic 
variants (Allen and Breathnach, 2006; Vandekerckhove et al., 2010). However, in recent years, 
an increased number of outbreaks of EHM and a high case fatality rate associated with EHM 
have been reported (Henninger et al., 2007; Perkins et al., 2009; Goehring et al., 2010; 
Gryspeerdt et al., 2011). Following a perceived increase in the incidence of EHM outbreaks 
over the last decade, the US Department of Agriculture classified EHM as a potentially 
emerging disease of equids (USDA-APHIS, 2007).  
 
1.2.6. Pathogenesis 
 
The equine alphaherpesviruses 
Primary EHV-1 and EHV-4 infections occur at the respiratory epithelium, resulting in distinct 
herpetic lesions of the upper respiratory epithelial mucosa and viral shedding for 10 to 14 days 
after infection, or even longer in EHM-affected horses (Allen et al., 2004; Lunn et al., 2009). 
EHV-1 spreads rapidly through the basement membrane of the respiratory mucosal epithelial 
cells by the misuse of trafficking resident immune cells and hence, the infection becomes 
systemic. Within 24 to 48 hours after infection, the cell-to-cell spread of EHV-1 results in the 
presence of virus in respiratory tract lymph nodes where further replication and infection of 
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leukocytes occurs (Kydd et al., 1994a). T-lymphocytes and monocytic lineage cells are 
identified as the predominant cell types infected with EHV-1 (Patel et al., 1982; Gryspeerdt et 
al., 2010; Vandekerckhove et al., 2011; Wilsterman et al., 2011). The cell-associated viremia 
arises at 24h post infection (Gryspeerdt et al., 2010) and can last till 9 to 23 days. The cell-
associated viremia allows the virus to reach the secondary sites of virus replication, particularly 
the endothelial cells of the pregnant uterus, the central nervous system, and the eye (Edington 
et al., 1986; Smith et al., 1993, 1996; Lunn et al., 2009; Hussey et al., 2013). This infection of 
endothelial cells ultimately induces abortion, myeloencephalopathy or chorioretinopathy 
(Smith et al., 1992; Kydd et al., 1994a, 1994b; Hussey et al., 2013) (Figure 4). 
 
The pathogenesis of EHV-1 abortion involves virus translocation from the circulation into the 
placenta, which causes infection of endothelial cells of the endometrium, leading to vasculitis, 
thrombosis, microcotyledonary infarction, and perivascular cuffing (Slater et al., 2006; Smith 
and Borchers, 2001). Severe infection of the endometrium leads to premature placental 
separation and abortion of a virologically negative fetus. However, in most cases, the virus can 
transfer across the uteroplacental barrier and affect the fetal viscera, which in turn leads to 
expulsion of a fetus with characteristic necrotic lesions and significant virus load (Cullinane et 
al., 2006).  
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Figure 4: The pathogenesis of EHV-1. The virus enters into the respiratory mucosa by 
inhalation, causing erosions in the respiratory mucosa. Via a cell-associated viremia, EHV-1 
spreads to the underlying tissues and further replicates in the local lymph nodes of the 
respiratory tract. Hereafter, the virus is transported to the endothelial cells of the pregnant 
uterus, the central nervous system, or the eye, hence leads to abortion, myeloencephalopathy, 
or chorioretinopathy. 
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The leukocyte-associated viremia to endothelial cells of small blood vessels of the brain or 
spinal cord results in damage to the microvasculature of the central nervous system due to 
initiation of an inflammatory cascade, vasculitis, microthrombosis, and extravasation of 
mononuclear cells resulting in perivascular cuffing and local hemorrhage (Edington et al., 1986; 
Lunn et al., 2009; Pusterla and Hussey, 2014). 
 
In contrast to EHV-1, EHV-4 infection remains in most cases limited to the upper respiratory 
tract causing a rhinopharyngitis and tracheobronchitis. The differences in the pathogenic 
potential of the two closely related viruses are mainly associated with (1) the variations in 
cellular tropism that is mainly determined by gD (absence of RSD motif, which is involved in 
the infection of PBMCs), (2) the inability of EHV-4 gG to modulate chemokines which are 
crucial for leukocyte migration, and (3) the rarity of a leukocyte-associated viremia (Osterrieder 
and Van de Walle, 2010; Vandekerckhove et al., 2011). 
 
EHV-3 is the causal agent of equine coital exanthema (ECE), an acute venereal mucocutaneous 
disease of horses characterized by the development of papules, vesicles, pustules and ulcers on 
the vaginal and vestibular mucosa, as well as on the skin of the penis, prepuce, and perineal 
region. The virus replicates in the stratified epithelium of epidermal tissues present at the 
mucocutaneous margins and skin. Destruction of the epithelium by the lytic virus infection 
elicits a vigorous inflammatory response that gives rise to the formation of characteristic 
cutaneous lesions of ECE (Allen and Umphenour, 2004; Barrandeguy and Thiry, 2012). 
 
The equine gammaherpesviruses 
EHV-2 and EHV-5 are most frequently transmitted horizontally to a newborn foal from its dam 
via the nasopharyngeal route or subsequently, through contact with other foals (Browning and 
Studdert, 1987; Bell et al., 2006). After inhalation, the virus infects the upper respiratory tract 
mucosal cells and B-lymphocytes probably at the site of draining lymphoid tissue (Borchers et 
al., 1997a; Gilkerson et al., 2015). Then, the lymphocyte-associated virus enters the circulation, 
disseminates systemically, and establishes latency (Allen and Murray, 2004). Periodic 
reactivation of latent infections can occur throughout the life of the horse, resulting in the spread 
of infection within a population. However, infections in later life appear mostly to be 
asymptomatic (Borchers et al., 1997a; Gilkerson et al., 2015). 
Introduction 
18 
1.2.7. Clinical signs  
 
Clinical signs associated with EHV-1 and EHV-4 
Respiratory disease: Respiratory disease caused by EHV-1 or EHV-4 is typically more 
widespread among young horses, with disease outbreaks most likely in the period between 
weaning and 2 - 3 years of age (Gilkerson et al., 2015). Older horses, which are partially 
immune as a result of earlier infections with EHV-1 or EHV-4, generally show a reduced 
duration and severity of respiratory tract disease (Wood et al., 2007). Infection is characterized 
by a short incubation time (< 1 day) followed by transient elevation of body temperature (38.9 
- 41.0°C), inappetence, nasal discharge, pharyngitis, depression, enlarged submandibular lymph 
nodes, and occasional ocular discharge. Affected horses usually give a few coughs, but 
coughing is not a major feature of uncomplicated equine herpesvirus respiratory disease (Patel 
and Heldens, 2005; Cullinane et al., 2006; Gilkerson et al., 2015). 
 
Abortion: EHV-1 is recognized as the most common cause of virus-induced abortion in 
pregnant mares. Pregnant mares infected with EHV-1 usually abort without prior clinical signs, 
most infection occurs late in gestation (8-11 months) and appear refractory to abortion if the 
virus is encountered earlier (less than 120 days) in gestation (Lunn et al., 2009; Slater, 2014). 
Prevalence of EHV-1 abortion in a group of mares varies, depending on management, degree 
of immunity, virulence of the virus, various stress factors, and the number of exposed 
susceptible mares in advanced pregnancy (Swerczek and Dennis, 2006). 
 
Myeloencephalopathy: The incubation periods of the EHM ranges from 6 - 8 days (Crabb and 
Studdert, 1995). The sudden onset and early manifestation of ataxia, paresis and urinary 
incontinence, the involvement of multiple horses on the premises, and a recent history of fever, 
abortion or respiratory disease in affected horse populations are typical features of EHM, 
although there is considerable variation between outbreaks with respect to epidemiological and 
clinical findings (Wilson, 1997). Commonly, the caudal spinal cord is more severely affected, 
resulting in weakness of hind limbs, bladder dysfunction, and sensory deficits in the perineal 
area. The onset of EHM typically occurs, often suddenly, between 6 to 10 days, often suddenly, 
and severity reaches a peak within 2 to 3 days (Pusterla and Hussey, 2014). 
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Chorioretinopathy: EHV-1-associated ocular lesions were first described in the late 1980’s in 
llamas and alpacas (Rebhun et al., 1988; House et al., 1991) and then in a mare and foal during 
natural outbreaks of paralytic EHV-1 and experimental infections (Whitwell and Blunden, 
1992; Hussey et al., 2013). EHV-1 infection of the ocular endothelium leads to 
chorioretinopathy, which causes permanent “shot- gun” lesions in a substantial proportion of 
infected horses (Hussey et al., 2013). Although the choroidal vasculature is typically hidden by 
the pigmented retinal epithelium, ocular lesions are not usually visible in vivo until one month 
or later after infection. Therefore, most ocular infections are subclinical and rarely lead to loss 
of function or even immediate symptoms. Lesions can be focal, multifocal, or rarely diffuse, in 
which case they affect the entire eye (Hussey et al., 2013; Pusterla and Hussey, 2014; Hussey 
and Landolt, 2015). 
 
Disease in neonatal foals: Some EHV-1 infected foals are apparently normal at birth but 
become weak, depressed, and die within 3 days with severe respiratory distress. Other infected 
foals may survive for a few weeks before succumbing to a variety of secondary bacterial or 
viral infections. The foals fail to nurse, become lethargic, pyrexic, leukopaenic, hypoxic, and 
exhibit severe respiratory distress and intractable diarrhea (Allen et al., 2004; Swerczek and 
Dennis, 2006). 
 
Clinical signs associated with EHV-3 
After an incubation period of 5-9 days, lesions appear as small (1-2 mm), raised and reddened 
papules, which often go unnoticed. Then, typical lesions of coital exanthema progress 
sequentially to a vesicle, a pustule and, after epidermal sloughing of the necrotic dome of a 
pustule, a shallow, raw or encrusted erosion or ulcer. The lesions heal within three weeks (Allen 
and Umphenour, 2004; Barrandeguy and Thiry, 2012). The infection has no effect on fertility 
and gestation, so the mare will carry the foal to term and deliver a healthy foal (Van der Meulen 
et al., 2006). Unilateral rhinitis associated with EHV-3 has also been reported (Barrandeguy et 
al., 2010b). From ECE outbreaks in Argentina, anorectal lymphadenopathy, constipation, 
tenesmus and evacuation of firm, dry, mucus-covered faces were reported in association with 
lesions around the anus (Barrandeguy et al., 2010a). Occasionally, stallions with extensive ECE 
lesions exhibit discomfort, loss of libido and refuse to mount and copulate with mares (Allen 
and Umphenour, 2004; Barrandeguy and Thiry, 2012). 
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Clinical signs associated with EHV-2 and EHV-5 
The disease association with EHV-2 or EHV-5 infections has been difficult to establish, as these 
viruses have been identified from clinically normal horses as well as from horses displaying 
respiratory disease. EHV-2 has been incriminated in mild respiratory disease (Dunowska et al., 
2002; Wang et al., 2007; Ataseven et al., 2010; Goehring, 2015), and keratoconjunctivitis 
(Kershaw et al., 2001; Rushton et al., 2016) while EHV-5 has been linked to occurrence of 
equine multinodular pulmonary fibrosis (EMPF) (Williams et al., 2007; Dunowska et al., 2014). 
Cases of EMPF have multiple coalescing nodules of fibrosis in the lung with histologic 
evidence of interstitial fibrosis and pneumonia with infiltrations of mixed inflammatory cells 
such as neutrophils and macrophages (Dunowska et al., 2014; Gilkerson et al., 2015). 
 
1.2.8. Diagnosis  
 
Despite a thorough anamnesis and a detailed clinical examination, it is usually not possible to 
diagnose any of the diseases associated with EHVs with certainty. In this context, a diagnostic 
laboratory support is necessary. Diagnostic assays used for the diagnosis of EHV infections are 
virus isolation, immunofluorescence, polymerase chain reaction (PCR)-based assays, and 
serologic analyses. Virus isolation remains the “gold standard” for laboratory diagnosis of EHV 
infections and provides unequivocal evidence of the presence of infectious virus in clinical 
samples such as respiratory tract, blood, fetal and placental tissue samples (Lunn et al., 2009; 
Slater, 2014; Hussey and Landolt, 2015). EHVs can be isolated on a variety of cell lines such 
as rabbit kidney cells, equine dermal cells, and equine embryonic lung cells. A positive EHV 
isolation is characterized by the appearance of cytopathic effects (CPE) in inoculated cultures. 
EHV-1, -3 and -4-induced CPE are normally detectable within 5 to 7 days of culture (Slater, 
2014), whereas CPE of EHV-2 and -5 is usually detected over 3 – 4 passages (Fortier et al., 
2010). 
 
PCR-based assays are extremely sensitive and have become key tools in the diagnosis of EHV 
infections. Positive PCR results can be obtained when virus isolation is negative due to 
inactivation of the virus or latent stage of the virus. With the use of specific primers, PCR can 
yield fast and accurate qualitative results. Several conventional PCR tests have been developed 
for the detection of DNA of the EHVs, with different type-specific primers capable of 
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distinguishing between the different EHVs (Kirisawa et al., 1993; Léon et al., 2008; Hue et al., 
2014). Conventional non-quantitative PCR results can be interpreted as follows (Lunn et al., 
2009): (1) a positive EHV-1 test result on a blood sample indicates viremia most probably 
resulting from an active infection; however, the detection of latent virus cannot be excluded; 
(2) a negative EHV-1 test result on a blood sample indicates the absence of detectable EHV-1 
viremia; (3) a positive EHV-1 test result on a nasal swab sample should be interpreted as 
indicative of the shedding of infectious virus; (4) a negative EHV-1 test result on a nasal swab 
indicates the absence of detectable virus shedding. More recently, quantitative real-time PCR-
based assays have also been employed for a more sensitive detection and quantitation of viral 
loads (Lunn et al., 2009; Slater, 2014). Determination of viral load can offer important 
advantages as it can allow for better characterization of disease stage, assessment of risk of 
exposure to other horses and monitoring of response to treatment (Lunn et al., 2009).  
 
Immunofluorescence (IF) tests can be used to demonstrate viral antigens in frozen tissue 
samples rapidly and with high sensitivity and specificity (Slater, 2014). Immunohistochemistry 
can be performed on paraffin-embedded, formalin fixed tissue sections to demonstrate viral 
antigens in infected epithelial and endothelial cells and provides valuable confirmation of the 
cause of vasculitis in the CNS and fetal tissues and placenta (Allen et al., 2004; Slater, 2007). 
 
Cerebrospinal fluid analysis from equids with EHM often reveals xanthochromia and increased 
protein concentrations, reflecting vasculitis and protein leakage into the cerebrospinal fluid 
(Van Maanen, 2002). These cerebrospinal fluid changes, in conjunction with characteristic 
clinical signs, are suggestive, but not diagnostic, of EHM (Slater, 2007).  
 
Serology can also be used to gain a retrospective diagnosis of EHV infections and forms a 
valuable part of longitudinal surveillance. Serologic testing which demonstrates a 4-fold or 
greater increase in serum antibody titer, by serum neutralizing (SN) or complement-fixation 
(CF) tests, on acute and convalescent samples collected 7-21 days apart provides presumptive 
evidence of an EHV-1 infection (Lunn et al., 2009). CF antibodies are short-lived, usually 
becoming undetectable by 3 months after infection (Kydd et al., 2006). The CF antibody test is 
therefore useful as an indicator of recent EHV-1 infection and during outbreaks of disease. In 
contrast, because of the longevity of SN antibodies (persisting for more than 9 months), SN test 
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is important for disease prevalence surveys (Kydd et al., 2006). However, neither SN nor CF 
test can distinguish antibodies to EHV-1 and EHV-4 (Slater, 2014). A commercially available 
enzyme-linked immunosorbent assay (ELISA), measuring antibodies directed against EHV gG, 
is capable of differentiating between EHV-1 and EHV-4 infection (Lunn et al., 2009; Slater, 
2014). 
 
1.2.9. Prevention and control 
 
Vaccination 
Eliminating EHV infections from the equine population is very challenging because of the early 
establishment of life-long latency, despite the presence of maternal antibody and the ability of 
the virus to modulate or suppress the host immune system (Kydd et al., 2006). Prevention of 
infectious diseases relies heavily on the use of vaccination. The purpose of EHV-1 vaccination 
is (1) to minimize virus replication in the respiratory tract upon infection, thus limiting nasal 
shedding and the occurrence of respiratory disorders, and (2) to prevent the occurrence of 
abortion and/or nervous system disorders. Currently, modified live virus and inactivated 
vaccines are available for protection against EHV-1 and EHV-4-induced disease. These 
vaccines induce high titers of CF and VN antibody and appear to offer some protection against 
respiratory disease. They reduce the duration and titer of nasal virus shedding of virus 
(Goehring et al., 2010; Bresgen et al., 2012). However, they do not reliably block infection, the 
development of viremia or the establishment of latency. Indeed, EHM has been observed in 
horses regularly vaccinated against EHV-1 at 3 to 5 monthly intervals (Lunn et al., 2009; 
Pusterla et al., 2009; Hussey and Landolt, 2015). Currently, extensive research is continuing to 
develop improved vaccines such as recombinant vaccines and DNA vaccines against EHV-1 
and EHV-4. To date, no vaccines are commercially available for preventing EHV-2, EHV-3, 
and EHV-5 infections. 
 
Management 
Rapid implementation of effective management practices in the event of an EHV outbreak is 
crucially important to prevent the spread of the virus among equids. The strategy for the control 
of EHV diseases should be a combination of management and hygiene measures supplemented 
by vaccination. EHV-1 disease control programs have three common goals: (1) prevention of 
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viral entry into premises; (2) limiting the extent of spread and severity of clinical disease once 
EHV-1 enters the premises or appears in the herd; and (3) limiting the viral spread to adjacent 
premises during an outbreak (Allen, 2002; Slater, 2007).  
 
Recommended herd management practices for prevention of abortion or neurological disorders 
in pregnant mares have been published as a ‘code of practice’ (Allen et al., 2004). The 
recommended procedures include (1) segregation of pregnant mares from all other horses on 
the premises, (2) isolation for a period of not less than 3 weeks of all mares entering the stud 
farm, including those that are returning after leaving the premises, (3) subdivision of pregnant 
mares into small physically separated groups for the duration of gestation, and (4) stress 
reduction by avoiding physiological stress: maintain social structures, avoid prolonged 
transport, relocation, poor nutrition, parasitism, environmental exposure, and en masse weaning 
of juveniles. 
 
1.3. Mucosa explants to study virus - host interactions 
 
1.3.1. Mucosal explants in research 
 
Experiments in living animals to study host-pathogen interactions is undesirable and raises 
ethical questions about animal welfare. In vivo experiments with large animals are difficult, as 
purchase and maintenance costs are high and suitable experimental animals are often difficult 
to obtain. Thus, there is a constant search for in vitro models that minimize the number of in 
vivo experiments and the use of experimental animals. The 3R principals (reduction, 
refinement, replacement) concerning the reduction of the number of experimental animals, the 
refinement of the experiments to minimize pain and distress, and the replacement of 
experimental animals by using ex vivo models, were set up by Russel and Burch in 1959 
(Russell and Burch, 1959). Explant models are powerful ex vivo tools permitting controlled 
experimental manipulation while maintaining microenvironment architecture (Anderson and 
Jenkinson, 1998). Variation between animals is minimized as tissues can be obtained from the 
same animal. Explant models may fulfill many of the above-mentioned requirements. In fact, 
the three-dimensional structure and normal cell-cell contacts are maintained in these models, 
thereby providing accessible means to mimic the in vivo situation. Explant models have proven 
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to be beneficial for the study of the interaction of bacterial or viral pathogens with the 
respiratory and/or the genital mucosae of different species such as pigs (Glorieux et al., 2007; 
Tulinski et al., 2013), horses (Vandekerckhove et al., 2009; Vairo et al., 2013), cows (Steukers 
et al., 2011), chickens (Reddy et al., 2014), cats (Li et al., 2015), dogs (Li et al., 2016) and 
humans (Maher et al., 2005; Glorieux et al., 2011; Steukers et al., 2014). 
 
1.3.2. General characteristics of respiratory and genital mucosae 
 
The respiratory epithelium  
The respiratory epithelium of the upper respiratory mucosa acts as the first physical barrier that 
protects against inhaled substances and pathogens. It is composed of the mucosa and the lamina 
propria. The respiratory epithelium has 5-7 rows of nuclei and a few intraepithelial 
lymphocytes. The mucosa is lined with pseudostratified ciliated columnar epithelium 
containing goblet cells, brush cells, basal cells, lymphoreticular tissue aggregates, and myeloid 
cells (Jeffery and Li, 1997). The lamina propria consists of loose irregular connective tissue 
with an increased concentration of subepithelial lymphocytes. Ciliated cells possess numerous 
cilia of uniform thickness. The round nuclei of pyramidal shaped basal cells are oriented in a 
linear row of the basement membrane and goblet cells located towards the supranuclear zone 
of the epithelium (Kumar et al., 2000). The mucus overlying the airway epithelium provides 
further protection of the mucosa by creating a semipermeable barrier that enables the exchange 
of nutrients, water, and gasses while being impermeable to most pathogens. It allows effective 
lung clearance through the mucociliary escalator (Vareille et al., 2011). Furthermore, it also 
contributes to the innate immune defense through antiviral and anti-inflammatory properties 
and through interaction with other mucus components such as IgA, collectins, and defensins 
(Vareille et al., 2011).  
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The vaginal epithelium 
The lower reproductive tract represents a unique site for pathogen entry. The vaginal wall of 
the mare consists of three layers: tunica mucosa-submucosa, tunica muscularis, and tunica 
adventitia or serosa. The tunica mucosa-submucosa is made up of the non-keratinized stratified 
squamous epithelium with abundant loose to dense irregular connective tissue below the 
epithelial lining. Stratified squamous epithelium, consisting of basal, middle, and superficial 
regions, covers the vaginal mucosa, which is arranged in longitudinal folds (Evans et al., 2009). 
An abrupt junction exists with the simple columnar epithelium on the protruding cervical folds 
at the external uterine orifice (McKinnon et al., 2011). The tunica adventitia contains loose 
connective tissue, blood vessels, nerves and ganglia (McEntee, 1991). The epithelium shows 
marked variation within the different areas of the vagina; it is thinner in the anterior region than 
in the vestibule. Epithelial cell proliferation and maturation are under hormonal regulation, and 
at peak estrogen levels the vaginal epithelium attains its maximum thickness with the superficial 
cells containing intracytoplasmic glycogen (Patton et al., 2000; Rosenfeld and Heide, 2008). 
The vaginal mucosa differs from other mucosae with respect to mucus composition, microbiota 
and innate and adaptive immune mechanisms (Kumamoto and Iwasaki, 2012). The acidic pH, 
epithelial barrier, mucus and innate immune responses triggered by the commensal flora act in 
concert to prevent virus infections in the female genital tract against pathogens (Kumamoto and 
Iwasaki, 2012). 
 
1.3.3. Cell-cell and cell-matrix adhesions 
 
Cells interact with their neighbors and the underlying extracellular matrix via specialized 
protein complexes that mediate adhesion, maintain structure, and transmit information to the 
cell interior about the environment (Balda and Matter, 2016). The integrity of the epithelial cell 
layer(s) that protects multicellular organisms from the external environment is maintained by 
intercellular junctional complexes composed of tight junctions, anchoring junctions (adherens 
junctions and desmosomes), and communicating junctions (gap junctions) (Schneeberger and 
Lynch, 2004). 
 
Tight junctions (zonula occludens) are the most apical of the intercellular junctions and are 
composed of transmembrane proteins that make contact across the intercellular space and create 
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a seal to restrict paracellular diffusion of molecules across the epithelial sheet (Sukita et al., 
2001; Schneeberger and Lynch, 2004). Tight junctions also have an organizing role in epithelial 
polarization by limiting the mobility of membrane-bound molecules between the apical and 
basolateral domains of the plasma membrane of each epithelial cell (Schneeberger and Lynch, 
2004; Balda and Matter, 2016). 
 
Anchoring junctions are responsible for the mechanical attachment of the cytoskeleton of a 
cell to another cell or to the extracellular matrix protein over discrete regions. Functionally, 
anchoring junctions can be classified into adherens junctions (or zonula adherens) and 
desmosomes (or macula adherens). Adherens junctions connect bundles of actin filaments from 
cell to cell to form a continuous adhesion belt, usually just below the tight junctions 
(Marchiando et al., 2010). Desmosomes connect keratin intermediate filaments from cell-to-
cell to form a structural framework of great tensile strength (Green and Simpson, 2007; 
Marchiando et al., 2010). 
 
Communicating junctions (gap junctions) are highly specialized membrane structures that 
contain clusters of channels. This organization requires the membranes of two neighboring cells 
to come close to each other leaving a 2-4 nm gap. The channels provide direct intercellular 
communication pathways allowing rapid exchange of ions and metabolites (Meşe et al., 2007; 
Goodenough and Paul, 2009). 
 
1.3.4. Extracellular matrix  
 
The extracellular matrix is the non-cellular component present within all tissues and organs and 
provides essential physical scaffolding for the cellular constituents and initiates crucial 
biochemical and biomechanical cues that are required for tissue morphogenesis, differentiation, 
and homeostasis. Within the mucosa, the extracellular matrix consists of the basement 
membrane and the lamina propria (Tanzer, 2006; Frantz et al., 2010).  
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The basement membrane 
The basement membranes are specialized extracellular matrices that coat the basal aspect of 
epithelial and endothelial cells, surround all muscle fibers, fat cells, and peripheral nerve cells. 
It has a structural role in maintaining tissue architecture and providing anchorage of adjacent 
cells, functions as a selective barrier to migrating or invading cells and, facilitates filtration or 
temporary storage of macromolecules (Marinkovich et al., 1993). The basement membrane has 
three component layers: the lamina lucida, the lamina densa, and the lamina reticularis. 
Together, the lamina lucida and lamina densa make up the basal lamina. The lamina lucida is a 
clear area between the epithelium and the lamina densa. The lamina densa is a sheet of 
connective tissue made up of type IV collagens, laminins, entactin, and heparin sulfate 
proteoglycans. The lamina reticularis is the interface between the basal lamina and the 
underlying connective tissue. The predominant collagen is type III, followed by collagens I, V, 
VI, and VII (Aumailley and Smyth, 1998; Evans et al., 2000; Kruegel and Miosge, 2010; 
Gartner, 2015). 
 
The lamina propria 
The lamina propria of the respiratory mucosa consists of a complex three-dimensional network 
of collagen, elastin fibers (fibrous proteins) and proteoglycans. This network is located 
underneath the basement membrane and harbors local cells (fibroblasts), mucus-producing 
glands, blood and lymphatic vessels and nerve endings (Alberts et al., 2002). The lamina propria 
of the vagina is well vascularized, but is aglandular (McKinnon et al., 2011). 
 
1.3.5. Mucosal immune cells 
 
Lymphocytes  
Intraepithelial lymphocytes associated with the respiratory and genitourinary tract epithelium 
are the first immune cells to encounter pathogens that have invaded an epithelial surface 
(Beagley and Husband, 1998). They appear to lie in an intercellular position at all depths of the 
epithelium, but most numerously near the base of the epithelium (Mair et al., 1987). Within the 
lamina propria of the respiratory epithelium, scattered small lymphocytes are present, however, 
their numbers are greatest in areas of the lamina propria adjacent to mucosal lymphoid tissue 
and just underneath the epithelium (Mair et al., 1987).  
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Myeloid cells 
Granulocytes and monocytes, collectively called myeloid cells, are differentiated descendants 
from common progenitors derived from hematopoietic stem cells in the bone marrow 
(Kawamoto and Minato, 2004). They represent the major leukocytes in the peripheral blood. 
Monocytes maturate into macrophages in various tissues. Macrophages are myeloid immune 
cells that are strategically positioned throughout the body tissues, where they ingest and degrade 
dead cells, debris, and foreign material and orchestrate inflammatory processes (Varol et al., 
2015).  
 
Monocytes may also differentiate into dendritic cells (DCs) in lymphoid organs and Langerhans 
cells in the skin, which function as professional antigen-presenting cells (Kawamoto and 
Minato, 2004). DCs are a heterogeneous population of antigen-presenting cells that initiate and 
orient immune responses (Steinman and Idoyaga, 2010). They have the ability to acquire 
antigen in infected tissues, to migrate to secondary lymphoid organs, and to provide the co-
receptor signals required for the effective helper and cytotoxic T-cell activation (Carbone and 
Heath, 2003). A specialized subset of DCs, the Langerhans cells (LCs), are located in the 
stratified squamous epithelial layer of the skin and within the mucosal epithelial lining of the 
vagina (Iijima et al., 2007).  
 
Mast cells are highly specialized cells of the myeloid lineage that are commonly encountered 
in mucosal and epithelial tissues near small blood vessels (Lunn and Horohov, 2004). They 
play a central role in inflammatory and immediate allergic reactions. They are able to release 
potent inflammatory mediators such as histamine, proteases, chemotactic factors, and cytokines 
that act on the vasculature, smooth muscle, connective tissue, mucous glands, and inflammatory 
cells (Amin, 2012). Mast cells are identified at all levels of the equine respiratory mucosa, with 
the greatest cell density in the nasopharynx. The majority (up to 94%) of this cell population is 
located within the connective tissue of the lamina propria and only small numbers are present 
within the surface epithelium (Mair et al., 1988). 
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Equine herpesviruses (EHVs) are distributed worldwide and are responsible for a variety of 
diseases in equids. The mucosal surface of the respiratory tract represents the principal portal 
of entry for EHVs. EHV-1 primarily replicates in the epithelial cells of the upper respiratory 
tract, after which it can spread throughout the body via a cell-associated viremia to the 
endothelial cells of the pregnant uterus, the central nervous system or the eye, resulting in 
abortion, myeloencephalopathy, or chorioretinopathy. Currently available vaccines against 
EHV-1 and EHV-4 do not reliably prevent infection, development of viremia or 
establishment of latency. To date, no specific therapy is effective against EHV infections. 
Thus, early recognition of the disease is very crucial for the implementation of management 
practices that decrease the risk of exposure of susceptible equids. Several epidemiological 
studies have been conducted on EHVs, but many data gaps exist and more investigation 
needs to be done to better understand the epidemiology of the disease in the different 
geographical settings and unvaccinated equine population.  
 
Mucosal tissues can differ significantly when it comes to structural barriers, 
microenvironment, and the composition of resident immune cells. This unique characteristic 
of different mucosal tissues influences the efficiency of replication and invasion of viruses. 
So far, studies have been conducted on the invasion characteristics of EHV-1 and EHV-4 in 
the equine respiratory mucosa. Initial infection starts with replication in the epithelial cells 
of the upper respiratory tract. EHV-4 infection is mostly limited to the respiratory tract, 
whereas EHV-1 is able to spread rapidly beyond the respiratory tract to become a systemic 
infection. In previous studies, the presence of EHV-1 has been reported in testis and semen 
of infected stallions, but their transmission through the vaginal mucosa is not known. 
Therefore, it is very interesting to evaluate the efficiency of EHV-1 invasion through the 
vaginal mucosa. Further unraveling of EHV-1 entry route via the vaginal mucosa may 
provide new insights into the pathogenesis of EHV-1. Infection with EHV-3 occurs through 
direct skin-to-skin contact during coitus or through secretions containing live virus, 
however, the underlying pathogenesis remains poorly understood. Thus, it is important to 
elucidate the viral behavior during the early stage of EHV-3 infection. A thorough 
understanding of EHV mucosal invasion mechanisms will provide new insights towards the 
development of alternative preventive and curative strategies. 
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Therefore, the first general aim of this doctoral thesis was to gain a better understanding of 
EHVs epidemiology. A second general aim was to obtain more insights into the invasion 
characteristics of two specifically chosen EHV types, namely EHV-1 and -3. 
 
The specific aims of this thesis were: 
 
 To isolate and genetically characterize EHV-1 from equids clinically affected with 
herpesvirus myeloencephalopathy during outbreaks in the Northern part of Ethiopia 
between 2011 and 2013 (Chapter 3.1).  
 To determine the prevalence of EHV-1, -2, -4, and -5 in Ethiopian equids with and 
without clinical signs of respiratory disease and genetically characterize EHV-2 and -5 
strains. For this purpose, a large cohort of equids was sampled in the Northern part of 
Ethiopia (Chapter 3.2). 
 To evaluate the replication kinetics and invasion characteristics of the neuropathogenic 
and abortigenic strains of EHV-1 and EHV-3 in the respiratory and genital mucosae using 
ex vivo tissue cultures (Chapter 4). 
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Abstract  
 
Although equine herpesvirus myeloencephalopathy (EHM) is a sporadic and relatively 
uncommon manifestation of equine herpesvirus-1 (EHV-1), it has the potential for causing 
devastating outbreaks in horses. Up till now, there were no reported EHM outbreaks in 
donkeys and mules. The present study describes the isolation and molecular characterization 
of EHV-1 from clinically EHM affected horses (n = 6), mules (n = 3), and donkeys (n = 82) 
in Ethiopia during outbreaks from May 2011 to December 2013. The incidence of EHM 
cases was higher from April to mid-June. However, EHM in donkeys was more severe and 
regularly death occurred after a short period of neurological signs. EHM-affected equids 
mainly observed over 3 years of age and equids within the age ranged from 7 - 10 years (n 
= 51; 56.0%) were mostly affected. Females (n = 58; 63.7%) were more affected than males. 
The incidence of neuropathogenic (D752) and non-neuropathogenic (N752) variants of EHV-
1 from EHM affected equids in Ethiopia was assessed by sequencing the DNA polymerase 
gene (ORF30) of the EHV-1 isolates. The results indicated that from the total of 91 clinically 
affected equids, 90 (98.9%) of them had an ORF30 D752 genotype. An ORF30 N752 variant 
was only found in 1 donkey. Analysis of ORF68 as grouping marker for geographical 
differences showed that the Ethiopian EHV-1 isolates belong to geographical group 4. Due 
to the fatal nature of EHV-1 in donkeys, it would be interesting to examine the pathogenesis 
of EHM in this species. At present, there is no vaccine available in Ethiopia, and therefore 
outbreaks of EHV-1 should be controlled by proper management adaptations. In addition, it 
is important to test the efficacy of the commercial vaccines not only in horses but also in 
donkeys and mules.  
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Introduction   
 
Equine herpesvirus 1 (EHV-1) is an important, ubiquitous viral pathogen in most equine 
populations throughout the world, which causes disease and extensive economic losses 
during frequent outbreaks of respiratory disease, abortion, neonatal foal death, 
myeloencephalopathy, and chorioretinopathy (Allen et al., 2004; Kydd et al., 2006; Hussey 
et al., 2013). EHV-1 is a member of the Alphaherpesvirinae of the family Herpesviridae, 
with a 150 kilobases double stranded DNA genome, consisting of 76 unique open reading 
frames (ORF) (Telford et al., 1992). 
 
EHV-1 establishes a lifelong infection (latency) in a high percentage of equids following 
exposure to the virus. Infections are particularly common in young performance horses and 
typically result in the establishment of a latent infection within the first months of life, with 
subsequent viral reactivation causing clinical disease and viral shedding during periods of 
stress (Goehring and Lunn, 2008). Outbreaks of EHV-1 neurological problems are thought 
to be initiated either by viral reactivation of latent EHV-1 (Allen and Timoney, 2007) or by 
virus transmission after a recent history of abortion or respiratory disease in an affected horse 
population (Pusterla et al., 2009).  
 
In recent years, there has been an unexpected increase in the incidence of equine herpesvirus 
neurological disease, equine herpesvirus myeloencephalopathy (EHM) (Perkins et al., 2009; 
Vissani et al., 2009; Fritsche and Borchers, 2010; Pronost et al., 2010; Smith et al., 2010). 
This EHM is classified as a potentially emerging disease by the US Department of 
Agriculture (USDA-APHIS, 2007). Studies suggested that EHM is strongly associated with 
a single nucleotide polymorphism (SNP) at position 2254 in the EHV-1 DNA polymerase 
gene ORF30 (Nugent et al., 2006; Goodman et al., 2007; Perkins et al., 2009). 
Neuropathogenic EHV-1 strains have been reported to replicate more efficiently and achieve 
10-fold higher levels of leukocyte-associated viremia as compared to horses infected with 
non-neurovirulent strains (Allen and Breathnach, 2006; Goodman et al., 2007; Van de Walle 
et al., 2009). A direct in vivo and ex vivo comparison of European EHV-1 strains has shown 
that more leukocytes are attracted and become infected in the nasal mucosa with the 
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neurovirulent strains compared with the non-neurovirulent strains (Gryspeerdt et al., 2010; 
Vandekerckhove et al., 2010).  
 
Infections with EHV-1 have been identified in other members of the family Equidae than 
horses, including mules and donkeys, which establish typically silent infections and serve as 
reservoir hosts (Van Maanen, 2002; Pusterla et al., 2012). Although all breeds of horses are 
susceptible to the neurologic form of EHV-1 infection, EHM from clinically affected 
donkeys and mules are poorly reported.  
 
According to a livestock survey, there are about 6.44 million donkeys, 1.96 million horses, 
and 373,519 mules recorded in Ethiopia (CSA, 2011). It has the largest equine population, 
probably with the highest density per square kilometer in the world (Feseha, 1998). These 
equids have an essential role in the livelihood of their owners and are mainly used for 
transportation, draught power, and other purposes. Recently, the Ministry of Agriculture of 
Ethiopia frequently received reports of outbreaks suspected of being induced by EHV-1 
(personal communications). Substantial numbers of equids (horses, mules, and donkeys) 
have died after showing clinical signs such as depression, anorexia, ataxia, and lameness. 
Because the etiology was never identified, the epidemiological situation of EHV-1 in 
Ethiopia was totally unknown. This study was designed for the isolation of EHV-1 and 
molecular characterization of the isolates from clinically affected horses, mules, and 
donkeys in Ethiopia.  
 
Materials and methods 
 
Outbreak investigation 
This study was conducted from May 2011 to December 2013 in the northern part of Ethiopia, 
especially in Amhara Regional State, an equine-dense population, where an outbreak of 
neurological problems was reported (Figure 1). Individual cases were clinically investigated. 
The following parameters were included: fever (rectal temperature ≥ 38oC for donkeys and 
≥ 38.5oC for horses and mules), respiratory problems, edema at the ventral region of the 
abdomen/limbs, abortion, neonatal foal death or neurological signs. Clinical and 
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epidemiological information were gathered and specimens were collected for EHV-1 
diagnosis.  
 
 
 
Figure 1: Map of Ethiopia that shows the districts where EHV-1 outbreaks were reported. 
1: Dembia, 2: Chilga, 3: Dera, 4: Bahir Dar Zuria, 5: Mecha, 6: South Achefer, 7: Dangla, 
8: Awabel, 9: Angolelana Tera, 10: Menz Keya Gebreal 
 
Sampling and processing protocol 
Nasopharyngeal swabs from apparently sick equids or tissue samples (spleen, thymus, liver, 
and/or lungs) from recently deceased equids were collected and transported in viral transport 
medium: phosphate buffered saline (pH of 7.2 - 7.6) with antibiotics. Whole blood samples 
were also collected from living animals using an EDTA vacutainer tube. The peripheral 
blood mononuclear cells (PBMCs) were separated by density gradient centrifugation using 
Ficoll-Paque PLUS (GE Health Care, Life Sciences). Each sample was labeled using a 
unique code consisting of the country (ETH), year of the outbreak (Y), and identification 
number (N). All collected samples were immediately placed in a cooler containing ice for 
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transport to the National Veterinary Institute, Ethiopia. Samples were kept at -70oC until 
further processing. 
 
Virus isolation 
Virus isolation from nasopharyngeal swabs, tissue suspension (10% w/v), and PBMCs were 
performed on confluent rabbit kidney (RK13) cells cultured in Dulbecco’s modified Eagle 
medium (DMEM) at 37oC in an atmosphere containing 5% CO2. The cells were monitored 
daily microscopically for the appearance of a cytopathic effect (CPE) for 7 days. If CPE was 
not detected, the cells were passaged blindly three times before the samples were declared 
negative. 
 
Nucleic acid extraction, PCR amplification, and sequencing 
EHV-1 DNA was extracted from 200µl of nasopharyngeal secretions, whole blood samples, 
and cell culture supernatant using a QIAamp DNA Mini Kit (Qiagen) according to the 
manufacturer’s instructions with a final DNA elution volume of 60µl. PCR assay was 
performed using Agilent’s Herculase II fusion DNA polymerase (Agilent Technologies, 
USA). DNA amplification was carried out in a final volume of 25µl PCR reaction mixtures 
containing 5µl of 5x Herculase II reaction buffer, 0.5µl of 25 mM each deoxynucleoside 
triphosphate (dNTP) mix, 0.5µl Herculase II fusion DNA polymerase, 1µl of each forward 
and reverse primers, 2.5µl of dimethyl sulfoxide (DMSO), 2.5µl of template DNA, and 12µl 
of nuclease-free water.  
 
The clinical diagnosis of EHV-1 was confirmed by PCR using specific primers (Table 1) 
targeting EHV-1 glycoprotein B and further sequence analysis. This protein contains highly 
specific regions that allow discrimination between closely related EHV-1 and EHV-4 
(Wagner et al., 1992; Borchers and Slater, 1993; Kirisawa et al., 1993).  
 
PCR amplification and subsequent sequencing of the DNA polymerase gene (ORF30) were 
performed using specific primers (Table 1) to amplify a region of 466bp, according to 
Goodman et al. (2007) to determine the prevalence of neurological and non-neurological 
variants (D752/N752) of EHV-1 from EHM affected equids in Ethiopia. The region of interest 
of ORF30 was amplified with an initial denaturation step of 95oC for 15 min, followed by 
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34 cycles of denaturation at 94oC for 1 min, annealing at 55.5oC for 1 min, extension at 72oC 
for 1 min, and a final extension at 72oC for 10 min.  
 
A 645bp region of ORF68 was also amplified using specific primers (see Table 1) and 
sequenced as described by Nugent et al. (2006). This sequence allows grouping of EHV-1 
isolates. The PCR consisted of an initial denaturation step of 94oC for 4 min, followed by 34 
cycles of denaturation at 94°C for 30 seconds, primer annealing for 1 min at 48oC, elongation 
72oC for 2 min, and a final extension at 72oC for 10 min. 
 
Table 1: Primers used for amplification and sequencing of specific regions of the genome 
of EHV-1. 
 
 
Amplicons of EHV-1 were detected by agarose gel electrophoresis and visualized under UV 
light after ethidium bromide staining. PCR products were purified using NucleoSpin®Gel 
and PCR Clean-up kit (Macherey-Nagel GmbH & Co. KG, Germany) in accordance with 
the manufacturer's instructions. The purified PCR products were sequenced by GATC 
Biotech, Germany, (ABI 3730XL Sanger sequencing platform) with sequencing primers. 
The genomic sequence of the parental EHV-1 strain Ab4, GenBank accession number 
AY665713, was used for comparison of sequences. 
 
Sequences were assembled and edited using the DNASTAR® software program, SeqMan 
Pro (version 12: DNASTAR, Inc.). Following sequence assembly, multiple alignments of 
Region PCR primers Use Size References 
 
ORF30 Fw: 5’-GCTACTTCTGAAAACGGAGGC-3’ PCR/Seq 466bp Goodman et 
al. (2007)  Rv: 5’-TATCCTCAGACACG GCAACA-3’ PCR/Seq 
ORF68 Fw: 5′- AGCATTGCCAAACAGTTCC-3’ PCR/Seq 645bp 
Nugent et 
al. (2006) 
 Rv: 5′-CAAGAAACCACTGCTCAACC-3’ PCR/Seq 
 S1: 5’-GAAGATAGAATGGGTGTGAG-3 Seq 
gB Fw: 5’- GCGTTATAGCTATCACGTCC-3’ PCR/Seq 190bp Kirisawa et 
al. (1993)  Rv: 5’- ATACGATCACATCCAATCCC- 3’ PCR/Seq 
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homologous sequences were analyzed using the ClustalW Multiple alignment programs 
implemented in BioEdit software version 7. A phylogenetic tree was constructed by the 
unweighted pair group method with arithmetic mean (UPGMA) using MEGA 6.06 software 
program. EHV-1 ORF68 genes of representative reference strains were retrieved from 
GenBank. 
 
Results 
 
Description of EHV-1 outbreaks 
During the period from May 2011 to December 2013, a total of 14 EHV-1 outbreaks in 10 
districts of Ethiopia were recorded. A total of 91 equids that showed clinical signs suggestive 
of EHM were included in this study, of which 82 of them were donkeys, 6 horses, and 3 
mules (Table 2). Outbreaks of EHM occurred during all seasons of the year, but a higher 
incidence of the disease was recorded from April to mid-June (data not shown).  
 
Table 2: Number of equids clinically affected by EHM during different years 
 
Sampling year 
Number of equids affected 
Horse Mule Donkey Total 
2011 0 0 33 33 
2012 0 0 7 7 
2013 6 3 42 51 
2011 - 2013 6 3 82 91 
 
In each outbreak, equids were carefully examined for the presence of characteristic clinical 
signs of EHM. Of the 91 EHM affected equids, 38 (41.8%) equids had raised rectal 
temperature, 7 (7.7%) had edema in the lower abdomen and/or hind limbs, 91 (100%) had 
ataxia and paresis (staggering movement), 1 (1.1%) had paralysis, and 1 (1.1%) had urinary 
incontinence. Furthermore, 11 (12.1%) equids had respiratory signs characterized by serous 
to mucopurulent nasal discharge (Table 3). There were no visible differences in the clinical 
presentation of EHM among horses, mules, and donkeys. However, However, EHM in 
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donkeys was more severe and regularly death occurred after a short period of neurological 
signs. 
 
Table 3: Clinical data observed in EHM-affected horses, mules, and donkeys 
 
Clinical signs 
Number of equids demonstrating the clinical signs (%) 
Horse 
(n = 6) 
Mule 
(n = 3) 
Donkey 
(n = 82) 
Total 
(n = 91) 
Fever 2 (33.3%) 1 (33.3%) 35 (42.7%) 38 (41.8%) 
Nasal discharge 2 (33.3%) 0 (0.0%) 9 (11.0%) 11 (12.1%) 
Edema on lower abdomen/limb 1 (16.7%) 0 (0.0%) 6 (7.3%) 7 (7.7%) 
Urinary incontinence 1 (16.7%) 0 (0.0%) 0 (0.0%) 1 (1.1%) 
Ataxia and paresis 6 (100%) 3 (100%) 82 (100%) 91 (100.0%) 
Paralysis  1 (16.7%) 0 (0.0%) 0 (0.0%) 1 (1.1%) 
 
The age of the EHM affected equids ranged from 2½ - 14 years (median 9 years), with 51 
(56%) equids at the age of 7 - 10 years. Only 2 donkeys were clinically affected at the age 
of less than 3 years. A higher proportion of EHM was recorded in females (58; 63.7%) than 
males (33; 36.3%) (Table 4). 
 
EHV-1 isolation and PCR detection 
EHV-1 was successfully isolated in confluent RK-13 cells from nasopharyngeal swabs, 
tissue samples (liver, lungs, thymus, and spleen), and PBMCs of equids showing clinical 
signs of EHM. Characteristic EHV-1 CPE (rounding, increase in refractility, and detachment 
of cells) were observed in the RK-13 monolayers. All isolates from EHM-affected equids 
were PCR positive using specific primers of EHV-1 gB, which allow the discrimination 
between EHV-1 and EHV- 4. During the investigation period, a total of 12 abortion cases 
were recorded and tissue samples from both aborted fetuses and placentas and whole blood 
samples were collected and examined for EHV-1 by isolation and PCR. All samples were 
negative.  
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Table 4: Intrinsic host risk factors associated with EHM observed within horses, mules, and 
donkeys 
 
Risk factors 
Number of equids demonstrating EHM (%) 
Horse (n = 6) Mule (n = 3) Donkey (n = 82) Total (n = 91) 
Age     
 < 3 years 0 (0.0%) 0 (0.0%) 2 (2.4%) 2 (2.2%) 
 4-6 years 1 (16.7%) 1 (33.3%) 19 (23.2%) 21 (23.1%) 
 7-10 years 5 (83.3%) 1 (33.3%) 45 (54.9%) 51 (56.0%) 
 > 10 years 0 (0.0%) 1 (33.3%) 16 (19.5%) 17 (18.7%) 
Gender     
 Male 1 (1.1%) 0 (0.0%) 32 (39.0%) 33 (36.3%) 
 Female 5 (83.3%) 3 (100%) 50 (61.0) 58 (63.7%) 
 
EHV-1 ORF30 sequence 
EHV-1 polymerase gene (ORF30) was PCR amplified and sequenced to estimate the 
prevalence of neurological (D752) and non-neurological (N752) variants of the virus. Of the 
91 clinically affected equids with neurological disorders, the ORF30 D752 variant was 
detected in 90 (98.9%) equids, of which 81 (98.8%) of them were donkeys, 3 (100%) mules, 
and 6 (100%) horses. An ORF30 N752 variant was found only in 1 (1.1%) donkey (Table 5).  
 
Table 5: Prevalence of N752 and D752 in the ORF30 gene of EHV-1 isolates from horses, 
mules, and donkeys 
 
 
 
Genotype 
Number of EHV-1 isolates (%) 
Horse (n = 6) Mule (n = 3) Donkey (n = 82) Total (n = 91) 
ORF30 N752     -      - 1 (1.22%) 1 (1.1%) 
ORF30 D752 6 (100%) 3 (100%) 81 (98.8%) 90 (98.9%) 
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EHV-1 ORF68 sequence 
EHV-1 ORF68 gene (nucleotides sequence 125,387 - 125,945 in EHV-1 Ab4, GenBank 
reference AY665713) was sequenced for all isolates and used to group the Ethiopian EHV-
1 isolates for geographical differences and compared to isolates from European countries, 
North and South America, and Australia according to Nugent et al. (2006). ORF68 was 
identical for all Ethiopian EHV-1 isolates and was categorized, according to the proposed 
classification in geographical group four (Figure 2). The ORF68 nucleotide sequences of the 
Ethiopian EHV-1 isolates were identical and therefore, a single nucleotide sequence from 
each species of equids was submitted to GenBank under accession numbers KP765722 from 
a horse, KP765723 from a mule, and KP765724 from a donkey. 
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Figure 2. Phylogenetic tree constructed by the UPGMA method using EHV-1 ORF68 
sequences. The first two or three letters indicate the country of origin, followed by the year 
of outbreak, unique identification number, and then the clinical outcome: non-
neuropathogenic (1) or neuropathogenic (2). The Ethiopian isolates have identical ORF68 
sequences and therefore, one sequence from the isolates of each equid species is used for the 
phylogenetic tree. ETH13_11_2 (KP765722) is an isolate from a horse; ETH13_54_2 
 DE12_ 1_1 (KJ513013.1)
 BE09_240_2 (GU271939.1)
 GB04_13_2 (DQ172345.1)
 FR00_1_1 (DQ172326.1)
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(KP765723) is an isolate from a mule; ETH13_56_2 (KP765724) is an isolate from a 
donkey. GenBank accession numbers are indicated in between parentheses.  
 
Discussion  
 
EHV-1 is the most prevalent virus in horse populations throughout the world that causes 
substantial equine losses. In this study, we describe the isolation and molecular 
characterization of EHV-1 from outbreaks of EHM in horses, mules, and donkeys in 
Ethiopia. These EHM outbreaks in Ethiopia are considered as emerging in working equids 
based on the following facts: (i) this is the first report of EHV-1-associated problems in the 
country, (ii) the outbreaks are increasing in time, (iii) large number of donkeys, horses, and 
mules are clinically affected, and (iv) the disease is spreading fast to different parts of 
Ethiopia. Prior to 2009, the presence of EHV-1 in equine populations had not been reported 
in Ethiopia (personal communication Ministry of Agriculture, Ethiopia). Since then, 
frequent and widespread EHV-1 outbreaks especially EHM have been described. During the 
period of 2011 to 2013, 14 EHM outbreaks in 10 districts of the country were recorded. In 
Ethiopia, the import of equids from other countries has not been documented. Therefore, the 
possible source of these EHV-1 outbreaks in Ethiopia is unknown. In recent years, outbreaks 
of EHM have been reported with increasing frequency and severity in most parts of the world 
(McCartan et al., 1995; van Maanen et al., 2001; USDA-APHIS, 2007; Damiani et al., 2014). 
Different risk factors are involved in the severity of the disease associated with EHV-1 
infection, including (i) the age and physical condition of the host, (ii) whether the infection 
is primary, a re-infection, or a reactivation of latent virus, (iii) the immune status of the host, 
and (iv) the pathogenicity of the strain involved (Allen et al., 2004; Allen, 2008).  
 
In this study, we observed that the EHM related clinical signs in donkeys were more severe 
(often fatal) than in horses and mules. This difference in severity might be associated with 
the host factor. Ethiopian donkeys might be highly susceptible to EHM infection. Barbic et 
al. (2012) reported a significant influence of breed on the clinical manifestation of 
neuropathogenic EHV-1 infections.  
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In the present study, a total of 91 clinically EHM affected equids were recorded, of which 
82 of them were donkeys, 6 horses, and 3 mules. EHM affected a larger proportion of 
donkeys than horses and mules. The present report of a clinical outcome of EHV-1 infections 
in donkeys and mules are in contrast to previous reports. Van Maanen (2002) stated that 
donkeys are an alternative host for EHV-1 and serve as a silent reservoir for infections in 
horses. Pusterla et al. (2012) reported that mules are protected against the development of 
neurological signs and that they are silent shedders of EHV-1 during an EHM outbreak 
among horses. To our knowledge, this is the first report of EHM affected donkeys and mules. 
The difference in the clinical outcome of EHV-1 infections in donkeys and mules might be 
explained by the fact that equids in Ethiopia are subjected to several stress factors such as 
heavy workload, traveling long distances, poor nutritional state, heavy parasite burden, and 
concurrent diseases. Another reason could be a difference in the pathogenic potential of 
EHV-1 strains. Horses, mules, and donkeys are sharing common paddocks, grazing pastures, 
and drinking places which might have led to trans-species transmission of the virus among 
horses, mules, and donkeys. 
 
Outbreaks of EHM were reported during all seasons of the year, but a higher incidence of 
EHM was observed from April till mid-June. Strong seasonal clustering of EHM outbreaks 
was described previously by Goehring et al. (2006), with all outbreaks occurring between 
mid-November and mid-May. This seasonal clustering of EHM outbreaks in late autumn, 
winter, and spring are associated with close confinement of equids (Lunn et al., 2009; Kydd 
et al., 2012). In Ethiopia this temporal clustering of EHM outbreaks is mainly associated 
with feed shortage, leading to a grouping of the animals in small pastures and paddocks and 
increasing stress.  
 
An increased body temperature was detected in 38 (41.8%) equids. The body temperature 
was measured during sampling from clinically affected equids. Previous studies on naturally 
occurring outbreaks of EHM indicated that fever occurs days before the onset of neurological 
signs, but is often absent during the neurological disorders (Henninger et al., 2007). 
Gryspeerdt et al. (2011) also reported the rapid occurrence of ataxia and paralysis 
immediately after the disappearance of fever. Therefore, in this study, the number of febrile 
EHV-1 myeloencephalopathy in Ethiopian equids    
67 
 
equids was higher than recorded before. The rise of body temperature should be considered 
as an early warning for EHM, which is in agreement with other studies. 
 
Mainly equids of 3 - 14 years (median 9 years) were clinically affected. Only 2 donkeys 
were showing clinical signs at the age of less than three years. This is consistent with 
previous studies. Goehring et al. (2006) reported that EHM was largely restricted to horses 
over 3 years of age. Allen and Breathnach (2006) observed a failure to develop neurological 
disease when yearling horses were experimentally infected with neuropathogenic strains of 
EHV-1. Although we clearly demonstrated that clinical EHM was largely restricted to equids 
over three years of age, the association of clinical manifestation of EHM and immunity 
remain to be determined. The highest proportion of equids was affected at the age ranging 
from 7 - 10 years. This is in line with other studies where the risk of EHM outbreaks was the 
highest in middle-aged or older horses (Barbic et al., 2012; reviewed by Pusterla and Hussey 
et al., 2014). In the present study, higher proportions of females were affected than males. 
This is also in line with what has been observed in other studies, where females in naturally 
occurring EHM are at higher risk of developing neurological problems (Goehring et al., 
2006; and Allen, 2008). At present, there is no clear explanation why both age and gender 
are related to the clinical outcome of an EHV-1 infection. 
 
Molecular epidemiological studies of EHV-1 have shown that a SNP in the DNA polymerase 
gene (ORF30), the change of adenine (A) to guanine (G) at nucleotide position of 2254 
resulting in an asparagine (N) to aspartic acid (D) change at amino acid position of 752, is 
strongly associated with outbreaks of highly lethal neurological disease in horses (Nugent et 
al., 2006; Van de Walle et al., 2009). Goodman et al. (2007) revealed that the point mutation 
of the DNA polymerase EHV-1 gene, from G2254 to A2254 encoding N752 instead of D752 
variants, results in a reduced virus replication in PBMCs, altered tropism for leukocyte 
subsets, and absence of neurological disease. In Ethiopia, 98.9% (90 out of 91) of EHV-1 
isolates were identified as neuropathogenic variants (D752), of which 81 (98.8%) of them 
were from donkeys, 6 (100%) from horses, and 3 (100%) from mules. Only 1 (1.22%) 
donkey, that displayed EHM, was infected with a non-neuropathogenic variant (N752). In 
general, 15 to 25% of EHM outbreaks are induced by non-neuropathogenic (N752) variants 
(Lunn et al., 2009). In this study, the prevalence of non-neuropathogenic variants from EHM 
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affected equids is far less than other reports in France (56%; 9/16) (Pronost et al., 2010), in 
Argentina (50%; 2/4) (Vissani et al., 2009), and in North America (24%; 5/21) (Perkins et 
al., 2009). The failure of EHV-1 detection from cases of abortion and the highly prevalence 
of neuropathogenic variants in EHM affected equids indicated that neuropathogenic variants 
are the main strains of EHV-1 circulating in equine populations in Ethiopia. To the author’s 
knowledge, EHM outbreaks were not reported earlier in the African continent. 
 
ORF68 of EHV-1, homologous to herpes simplex virus type-1 Us2, has the highest sequence 
variation rate (2%) and is used as a grouping marker and provide evidence for geographical 
restriction of certain genotypes (Nugent et al., 2006). Based on mutations at nucleotide 
positions 336, 344, 629, 710, 713, 719, 731-740 and 755, strains from North America, South 
America, Europe, and Australia were classified into six geographical groups. The present 
study showed that the Ethiopian EHV-1 strains are assigned to group four. In this group, 
strains from the USA and European countries such as Germany, Belgium, Great Britain, and 
France were present. This indicates that in one way or another this virus entered Ethiopia in 
the past, leading to the current problems.  
 
In conclusion, EHV-1 has been isolated and genetically characterized for the first time from 
EHM outbreaks in working equids of Ethiopia. It documents that donkeys and mules, besides 
horses, are clinically affected by the neurological form of EHV-1. The neuropathogenic 
variant of EHV-1 was mainly responsible for the EHM outbreaks and all the Ethiopian EHV-
1 isolates were allocated to geographical group 4. EHM outbreaks have been the most 
prevalent clinical outcome of the EHV-1-associated diseases and caused devastating losses 
of equids especially in donkeys. Based on the relatively fast course and fatal nature of the 
EHV-1 infection in donkeys, it is worth studying the pathogenesis of EHM in donkeys both 
in vivo (ex vivo) and in vitro. Because available vaccines have never been evaluated in 
donkeys and mules, it is not clear to what degree they may give protection in these equid 
species. More work is needed to get an answer to this question.  
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Abstract 
 
Infections with equine herpesviruses (EHVs) are widespread in equine populations 
worldwide. Whereas both EHV-1 and EHV-4 produce well-documented respiratory 
syndromes in equids, the contribution of EHV-2 and EHV-5 to disease of the respiratory 
tract is still enigmatic. The present study describes the detection and genetic characterization 
of EHVs from equids with and without clinical respiratory disease. Virus-specific PCRs 
were used to detect EHV-1, -2, -4, and -5. From the total of 160 equids with respiratory 
disease, EHV-5 was detected at the highest prevalence (23.1%), followed by EHV-2 
(20.0%), EHV-4 (8.1%), and EHV-1 (7.5%). Concurrent infections with EHV-2 and EHV-
5 were recorded from 9 (5.2%) diseased horses. Of the total of 111 clinically healthy equids, 
EHV-1 and EHV-4 were never detected whereas EHV-2 and EHV-5 were found in 8 (7.2%) 
and 18 (16.2%) horses, respectively. A significantly higher proportion of EHV-2-infected 
equids was observed in the respiratory disease group (32/160, 20.0%; P = 0.005) compared 
to those without disease (8/111; 7.2%). EHV-2-positive equids were three times more likely 
to display clinical signs of respiratory disease than EHV-2-negative equids (OR 3.22, 95% 
CI: 1.42 to 7.28). For EHV-5, the observed difference was not statistically significantly (P 
= 0.166). The phylogenetic analysis of the gB gene revealed that the Ethiopian EHV-2 and 
EHV-5 strains had a remarkable genetic diversity, with a nucleotide sequence identity among 
each other that ranged from 94.0 to 99.4% and 95.1 to 100%, respectively. Moreover, the 
nucleotide sequence identity of EHV-2 and EHV-5 with isolates from other countries 
acquired from GenBank ranged from 92.9 to 99.1% and 95.1 to 99.5%, respectively. Our 
results suggest that besides EHV-1 and EHV-4, EHV-2 is likely to be an important 
contributor either to induce or predispose equids to respiratory disease. However, more work 
is needed to better understand the contribution of EHV-2 in the establishment of respiratory 
disease. 
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Introduction 
 
Equine herpesvirus 1 (EHV-1) and equine herpesvirus 4 (EHV-4) are closely related 
alphaherpesviruses that cause economically important diseases in equids globally. They are 
among the most common respiratory tract pathogens in equids  (Allen et al., 2004; Gonzalez-
Medina & Newton, 2015). EHV-4 mainly infects epithelial cells whereas EHV-1 also infects 
immune cells, helping the virus to spread rapidly through the basement membrane of the 
respiratory mucosal epithelial cells and causing a systemic infection, resulting in abortion, 
myeloencephalopathy, and chorioretinopathy (Allen et al., 2004; Lunn et al., 2009; Hussey 
et al., 2013). 
 
Equine herpesvirus 2 (EHV-2) and equine herpesvirus 5 (EHV-5) are distinct, but closely 
related, equid gammaherpesviruses that have been detected in equine populations worldwide 
(Allen and Murray, 2004). Although the clinical importance is less clearly defined, reports 
suggest that they are associated with certain disease complaints, such as respiratory disease 
(Dunowska et al., 2002; Wang et al., 2007; Ataseven et al., 2010), keratoconjunctivitis 
(Kershaw et al., 2001; Rushton et al., 2016, 2013), and multinodular pulmonary fibrosis 
(Williams et al., 2007; Dunowska et al., 2014).  
 
The establishment of lifelong latency in a large proportion of infected animals ensures the 
survival of herpesviruses in equine populations and enables the virus to be shed sporadically 
throughout the lifetime of the host (Gilkerson et al., 2015; Gonzalez-Medina and Newton, 
2015). EHV-1 and EHV-4 enter into a latent state in cells of the lymphoreticular system and 
neurons in the trigeminal ganglia (Slater et al., 1994). EHV-2 is latent in B-lymphocytes, 
macrophages, and possibly Langerhans cells (Drummer et al., 1996; Borchers et al., 1997; 
Allen and Murray, 2004). The latency sites for EHV-5 are unknown (Gilkerson et al., 2015; 
Goehring, 2015). 
 
Approximately 60% of the world’s horse population and over 95% of all donkeys and mules 
are found in developing countries (Pritchard et al., 2005). Ethiopia possesses approximately 
half of Africa’s equine population. According to the United Nation Food and Agriculture 
Organization, there are over 7 million donkeys, mules, and horses in Ethiopia (Anonymous, 
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2010). These working equids have an essential role in the livelihoods of millions of people 
in Ethiopia. Infectious diseases are an important constraint to the health and productivity of 
equines. Respiratory viral diseases, especially those caused by EHVs, have been identified 
as one of the major health threats to equids, which cause significant economic losses (Allen 
et al., 2004; Lunn et al., 2009). Despite the economic significance of EHVs, studies on the 
occurrence and the epidemiology of these viruses in Ethiopian working equids are limited. 
Therefore, the present study was designed to detect and genetically characterize EHVs from 
equids with and without clinical respiratory disease and to examine the association between 
respiratory disease and EHV infections. 
 
Materials and methods 
 
Study area and sampling 
This study was conducted from September 2015 to March 2016 in selected districts of the 
northern part of Ethiopia (Angolelana Tera, Abichuna Gnea, and South Achefer) (Figure 1), 
where large numbers of equids and a high incidence of EHV-1 outbreaks were recorded 
(CSA, 2014; Negussie et al., 2015). A total of 271 equids at the age ranging from 6 months 
to 13 years (median: 5.6 years) were included in this study, of which 111 were clinically 
normal and 160 had clinical signs associated with respiratory disease such as serous to 
mucopurulent nasal discharge and/or coughing, accompanied with fever (rectal temperature 
> 38oC for donkeys and > 38.5oC for horses). From the total of 160 clinically sick equids, 
62 whole blood (donkeys = 24; horses = 38) and 98 nasal swab samples (donkeys = 17; 
horses = 81) were collected for the detection of EHV-1, -2, -4, and -5. Similarly, from the 
total of 111 clinically normal equids, 51 whole blood (donkeys = 8; horses = 43) and 60 
nasal swab samples (donkey = 2; horses = 58) were collected. All collected samples were 
immediately placed in a cooler containing ice for transport to the National Animal Health 
Diagnostic and Investigation Center, Ethiopia. The peripheral blood mononuclear cells 
(PBMCs) were separated by density gradient centrifugation using Ficoll-Paque PLUS (GE 
Health Care, Little Chalfont, Buckinghamshire, UK). Samples were kept at -70°C until 
further processing. 
  Chapter 3.2 
79 
 
Figure 1: Map of Ethiopia that shows the districts where blood and nasal swab samples were 
collected from equids with and without respiratory tract disease. 1, South Achefer; 2, 
AngolelanaTera; 3, Abichuna Gnea 
 
DNA extraction, PCR amplification and sequencing 
Viral DNA was extracted from 200µl of PBMCs and nasal swab samples using the QIAamp 
DNA Mini Kit (Qiagen) according to the manufacturer's instructions. Sensitive virus-
specific PCRs targeting the conserved region of glycoprotein B genes were used for each 
specimen to identify EHV-1, -2, -4, and -5. PCR amplification and subsequent sequencing 
were performed using virus primers that were specific for the detection and differentiation 
of closely related viruses such as EHV-1 and EHV-4 (Kirisawa et al., 1993; Léon et al., 
2008) and EHV-2 and EHV-5 (Holloway et al., 1999; Dynon et al., 2001; Diallo et al., 2008) 
(Table 1). PCRs were performed using Agilent’s Herculase II fusion DNA polymerase 
(Agilent Technologies, Inc., Santa Clara, CA, USA). Each of the 25µl PCR mixtures 
contained 12.5µl of nuclease-free water, 5µl of 5 x Herculase II reaction buffer, 0.5µl 
Herculase II fusion DNA polymerase, 0.5µl of 25 mM each deoxynucleoside triphosphate 
(dNTP) mix, 1µl of each forward and reverse primers, 2.5 µl of dimethyl sulphoxide 
(DMSO), and 2µl template DNA. In each reaction, a positive control (EHV strains that were 
1
3
2
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isolated and confirmed by sequence analysis) and a negative control (nuclease-free water) 
were included. 
 
Table 1: Primers used for amplification and sequencing of a specific region of the gB gene 
of equine herpesviruses 
 
 
The region of interest targeting EHV-1 and EHV-4 gB genes were amplified with an initial 
denaturation step of 94oC for 5 min, followed by 40 cycles of denaturation at 94oC for 30 s, 
annealing at 64oC for 30 s, extension at 72oC for 1 min and 30 s, and a final extension at 
72oC for 10 min. Similarly, EHV-2 and EHV-5 were amplified using the following 
thermocycling conditions: an initial denaturation step of 95°C for 5 min, followed by 40 
cycles of amplification, using denaturation at 95°C for 30 s, annealing at 60oC, and extension 
at 72oC for 45 s and followed by a final extension at 72 °C for 10 min. As a negative control, 
nuclease-free water was used. 
 
The final specific PCR products were visualized using 1.5% agarose gel electrophoresis. The 
gels were examined for specific size bands using a UV transilluminator. The PCR products 
were purified with QIAquick Gel extraction kit (Qiagen) and sequenced by BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on 
genetic analyzer 3130 (Applied Biosystems) using the same forward and reverse primers as 
previously described.  
  
Virus Region  PCR Primers Size  Reference 
 
EHV-1 gB FW: 5’-GCGTTATAGCTATCACGTCC-3’ 190 bp Kirisawa et 
al. (1993) RV: 5’-ATACGATCACATCCAATCCC-3’  
EHV-2 
 
gB FW: 5’-GCCAGTGTCTGCCAAGTT GATA-3’ 444 bp Diallo et al. 
(2008) RV: 5’-CATGGTCTCGATGTCAAACACG-3’  
EHV-4 gB FW: 5’-CCTGCATAATGACAGCAGTG-3’ 677 bp Kirisawa et 
al. (1993)  RV: 5’-ATACGATCACATCCAATCCC-3’  
EHV-5 gB FW: 5' ATGAACCTGACAGATGTGCC 3' 293 bp Holloway et 
al. (1999)   RV: 5' CACGTTCACTATCACGTCGC 3'   
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Sequence analysis 
Sequences were assembled and edited using the DNASTAR software program, SeqMan Pro 
(version 12; DNASTAR, Inc., Madison, WI, USA). Following sequence assembly, multiple 
alignments of homologous sequences were analyzed using the ClustalW Multiple alignment 
programs implemented in BioEdit software version 7. A phylogenetic tree was constructed 
using the neighbor-joining method in MEGA 6.06 software program. Representative genes 
of reference strains were retrieved from GenBank. The nucleotide sequences of EHV-2 and 
EHV-5 strains reported in this studies were submitted to GenBank under the accession 
number from KX549262 to KX549274. 
 
Statistical analysis 
The data were analyzed using SPSS version 20 software (SPSS Inc., Chicago, USA). Pearson 
Chi-Square test was used to compare the significant difference between the risk factors and 
EHV infection. The associations between EHV-2 or EHV-5 detection and displaying of 
clinical signs of the respiratory disease was computed using logistic regression. Differences 
were considered statistically significant when P-value was < 0.05. 
 
Results  
 
The prevalence of EHV-1, -2, -4, and -5 in equids displaying respiratory disease 
Virus-specific PCRs were used to detect EHV-1, EHV-2, EHV-4, and EHV-5 from a total 
of 160 donkeys and horses exhibiting clinical signs of respiratory disease (nasal discharge 
and/or coughing, accompanying with fever). EHV-5 was detected at the highest prevalence 
(37/160; 23.1%), followed by EHV-2 (32/160; 20.0%), EHV-4 (13/160; 8.1%), and EHV-1 
(12/160; 7.5%) (Table 2). Concurrent infections with EHV-2 and EHV-5 were recorded from 
9 (5.2%) diseased horses. 
 
From the total 62 blood and 98 nasal swab samples collected from equids with signs of 
respiratory tract disease, EHV-1 was detected from 5 (8.1%) blood and 7 (7.1%) nasal swab 
samples, EHV-2 was detected from 13 (20.9%) blood and 19 (19.4%) nasal swab samples, 
EHV-4 was detected from 13 (13.3%) nasal swab samples, and EHV-5 was detected from 
19 (30.6%) blood and 18 (18.4%) nasal swab samples.  
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Both species of equids were infected with EHV-1, with a significantly (P = 0.001) higher 
prevalence in donkeys (8/41; 19.5%) compared to horses (4/119; 3.4%). Similarly, the 
prevalence of EHV-4 was somewhat higher in donkeys (4/41; 9.8%) than horses (9/119; 
7.6%), however, this difference was not statistically significant (P = 0.658). A significantly 
(P = 0.005) higher prevalence of EHV-2 and EHV-5 were recorded in horses (EHV-2 
(30/119; 25.2%); EHV-5 (34/119; 28.6%)) compared to donkeys (EHV-2 (2/41; 4.9%); 
EHV-5 (3/41; 7.3%)).  
 
Table 2: The prevalence of EHV-1, -2, -4, and -5 from donkeys and horses displaying 
clinical signs of respiratory disease 
 
 
Risk factors 
No. of 
equids 
The proportion of equids with respiratory disease that 
are positive for ….. 
 
EHV-1 EHV-2 EHV-4 EHV-5 
 
Species       
 Horses  119 4 (3.4%) 30 (25.2%) 9 (7.6%) 34 (28.6%) 
 Donkeys 41 8 (19.5%) 2 (4.9%) 4 (9.8%) 3 (7.3%) 
Gender       
 Males  48 2 (4.2%) 8 (16.7%) 6 (12.5%) 8 (16.7%) 
 Females  112 10 (8.9%) 24 (21.4%) 7 (6.2%) 29 (25.9%) 
Age      
 < 3 years 55 5 (9.1%) 13 (23.6%) 6 (10.9%) 14 (25.5%) 
 4-6 years 62 4 (6.5%) 11 (17.7%) 6 (9.7%) 15 (24.2%) 
 7-10 years 34 3 (8.8%) 7 (20.6%) 0 (0.0%) 6 (17.6%) 
 > 10 years 9 0 (0.0%) 1 (11.1%) 1 (11.1%) 2 (22.2%) 
 
Total no. of equids  160 12 (7.5%) 32 (20.0%) 13 (8.1%) 37 (23.1%) 
 
Although not significantly different, a higher prevalence of EHV-1, EHV-2 and EHV-5 was 
recorded in females (EHV-1 (10/112; 8.9%; P = 0.295); EHV-2 (24/112; 21.4%; P = 0.490); 
EHV-5 (29/112; 25.9%; P = 0.205)) than in males (EHV-1 (2/48; 4.2%); EHV-2 (8/48; 
16.7%); EHV-5 (8/48; 16.7%)). In contrast, a higher prevalence of EHV-4 was detected in 
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males (6/48; 12.5%) compared to females (7/112; 6.2%), but the difference was also not 
statistically significant (P = 0.185).  
 
The age distribution was highly variable ranging from 6 months to 13 years (median: 5.6 
years). As shown in Table 2, the animals were classified in the following age groups: less 
than 3 years (n = 55), 4 to 6 years (n = 62), 7 to 10 years (n = 34), and older than 10 years (n 
= 9). There was no statistically significant difference among the age groups with EHV 
infections. However, a higher prevalence of EHV-1 (5/55; 9.1%; P = 0.774), EHV-2 (13/55; 
23.6%; P = 0.776), EHV-4 (6/55; 10.9%; P = 0.274), and EHV-5 (14/55; 25.5%; P = 0.853) 
was recorded at an age less than three years compared to the other age groups. 
 
The prevalence of EHV-1, -2, -4, and -5 in clinically healthy equids 
The prevalence of EHV infections was also evaluated from a total of 111 clinically healthy 
donkeys and horses. EHV-1 and EHV-4 were never detected. EHV-2 and EHV-5 were 
detected from 8 (7.2%) and 18 (16.2%) horses, respectively. Coinfections with EHV-2 and 
EHV-5 were not detected from clinically healthy equids (Table 3).  
 
From the total of 51 blood and 60 nasal swab samples collected from clinically healthy 
equids, EHV-2 was detected from 5 (9.8%) blood and 3 (5.0%) nasal swab samples, whereas 
EHV-5 was detected from 11 (21.6%) blood and 7 (11.7%) nasal swab samples.  
 
Although not significantly different, the prevalence of EHV-2 was higher in males (3/39; 
7.7%; P = 0.884) compared to females (5/72; 6.9%), whereas the prevalence of EHV-5 was 
higher in females (14/72; 19.4%; P = 0.210) than males (4/39; 10.3%).  
 
A higher prevalence of EHV-2 (3/36; 8.3%; P = 0.986) and EHV-5 (7/36; 19.4%; P = 0.337) 
was recorded at an age less than three years, but the difference was not statistically 
significant. 
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Association between EHV-2 or EHV-5 detection with the presence of respiratory 
disease  
The association of the presence of EHV-2 or EHV-5 with respiratory clinical signs was 
evaluated by comparing the diseased and healthy group. A significantly higher proportion 
of EHV-2-infected equids was observed in the respiratory disease group (32/160, 20.0%; P 
= 0.005) compared to those without disease (8/111; 7.2%). EHV-2-positive equids were 
three times more likely to display clinical signs of respiratory disease than EHV-2-negative 
equids (OR 3.22, 95% CI: 1.42 to 7.28). However, a significant association (P = 0.166) was 
not observed between EHV-5-infected equids in the respiratory disease group (37/160; 
23.1%) and those not demonstrating signs of respiratory disease (18/111; 16.2%). 
 
Table 3: The prevalence of EHV-1, -2, -4, and -5 detected from clinically healthy equids  
 
 
Risk factors 
No. of 
equids 
The proportion of equids that are positive for … 
 
EHV-1 EHV-2 EHV-4 EHV-5 
 
Species      
 Horses  101 0 (0.0%) 8 (7.9%) 0 (0.0%) 18 (17.8%) 
 Donkeys 10 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Gender       
 Males  39 0 (0.0%) 3 (7.7%) 0 (0.0%) 4 (10.3%) 
 Females  72 0 (0.0%) 5 (6.9%) 0 (0.0%) 14 (19.4%) 
Age        
 < 3 years 36 0 (0.0%) 3 (8.3%) 0 (0.0%) 7 (19.4%) 
 4-6 years 33 0 (0.0%) 2 (6.1%) 0 (0.0%) 6 (18.2%) 
 7-10 years 27 0 (0.0%) 2 (7.4%) 0 (0.0%) 5 (18.5%) 
 > 10 years 15 0 (0.0%) 1 (6.7%) 0 (0.0%) 0 (0.0%) 
 
Total no. of equids 111 0 (0.0%) 8 (7.2%) 0 (0.0%) 18 (16.2%) 
 
Phylogenetic analysis  
The partial nucleotide and amino acid sequences of the gB gene of seven EHV-2 and seven 
EHV-5 strains obtained from Ethiopian donkeys and horses were compared with each other 
  Chapter 3.2 
85 
and with the sequences of strains from other countries acquired from GenBank (Figure 2). 
The Ethiopian EHV-2 strains had a genetic diversity, with a nucleotide sequence identity 
among each other that ranged from 94.0 to 99.4%, and an amino acid sequence identity that 
ranged from 90.2 to 98.3%. The degree of similarity between Ethiopian strains and foreign 
EHV-2 strains ranged from 92.9 to 99.1% at nucleotide level and from 87.8 to 98.3% at 
amino acid level. Similarly, a genetic heterogeneity was observed among Ethiopian EHV-5 
strains at nucleotide and amino acid level, with an overall identity of 95.1 to 100% and 94.7 
to 100%, respectively. Moreover, EHV-5 showed 95.1 to 99.5% nucleotide and 94.7 to 
98.6% amino acid sequence identity with isolates from other countries retrieved from 
GenBank. 
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Figure 2: Phylogenetic tree constructed by neighbor-joining method using the gB gene of 
EHV-2 and EHV-5 from Ethiopian equids. The first two, three or four letters indicate the 
country of origin followed by strain of the herpesvirus, and then unique identification 
number. ETH_EHV5(20) (KX549267) and ETH_EHV2(23) (KX549270) are strains from 
donkeys, while the other strains are from horses. GenBank accession numbers are indicated 
in between parentheses.  
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Discussion 
 
Respiratory pathogens are important causes of disease in equine populations worldwide. 
Although multiple causative agents are involved, viral pathogens play an important role in 
establishing equine respiratory disease. The EHVs are important viral agents that are 
involved in equine respiratory problems of varying severity (Allen et al., 2004; Reed and 
Toribio, 2004). In the present study, the detection and genetic characterization of EHVs from 
equids with and without respiratory disease are described and the association between 
respiratory disease and EHV infection is examined. Previously, we described the EHV-1-
associated myeloencephalopathy outbreaks in Ethiopian equids (Negussie et al., 2015). In 
the present study, we also provide the first molecular evidence of EHV-1, EHV-2, EHV-4, 
and EHV-5 infection in Ethiopian donkeys and horses with and without respiratory 
problems. A total of 12 (7.5%) and 13 (8.2%) equids exhibiting clinical signs of respiratory 
disease were infected with EHV-1 and EHV-4, respectively. There is unequivocal evidence 
that EHV-1 and EHV-4 are major pathogens that cause acute respiratory disease in equids 
as described elsewhere (Gilkerson et al., 2015). Similarly, 32 (20.0%) and 37 (23.1%) equids 
with signs of clinical respiratory disease were infected with EHV-2 and EHV-5, respectively. 
The prevalence of EHV-2 and EHV-5 infections in Ethiopian equids is consistent with a 
report from Turkey (Ataseven et al., 2010), but relatively lower than other reports from 
Sweden, Hungary and UK (Back et al., 2009; Nordengrahn et al., 1996) and Australia (Wang 
et al., 2007). EHV-5 was detected at a higher prevalence than EHV-2, which is in agreement 
with other reports from Australia (Wang et al., 2007; Diallo et al., 2008) and Turkey 
(Ataseven et al., 2010), but in contrast to studies from Sweden, Hungary and UK 
(Nordengrahn et al., 2002), New Zealand (Dunowska et al., 2002) and Iceland (Torfason et 
al., 2008), where EHV-2 has been more commonly identified. These data indicated that the 
prevalence of EHV-2 and EHV-5 infections in equine populations are geographically 
variable, which might be influenced by the breeds of equids and environmental factors. 
 
In this study, EHV-1, -2 and -5 were detetcted from blood and nasal swab samples collected 
from equids with respiratory disease. EHV-4 was detected only from nasal swab samples. 
Detection of EHVs in blood samples demonstarting the presence of viremia, probably 
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resulting from lytic infection, whereas dectection of EHVs in the nasal swab samples suggest 
viral shedding.  
 
In this study, concurrent infections with EHV-2 and EHV-5 were recorded in 9 (5.2%) horses 
with respiratory disease. Co-infection was not detected in donkeys. This dual infection is 
consistent with other reports (Nordengrahn et al., 2002; Back et al., 2009; Ataseven et al., 
2010), in which both viruses can simultaneously infect horses. Although we clearly 
demonstrated that dual infections may be detected in horses exhibiting clinical signs of 
respiratory disease, their synergistic pathogenic effect on the respiratory tract remains to be 
determined. 
 
In the current study, both equid species were infected with EHV-1, with a significantly 
higher prevalence in donkeys compared to horses. This is in line with the previous report of 
neurological EHV-1 outbreaks in Ethiopia (Negussie et al., 2015), where a larger population 
of donkeys was affected than horses. The higher prevalence of EHV infections in Ethiopian 
donkeys might be associated with (1) host factors (Ethiopian donkeys may be more 
susceptible to EHV infections than horses) and/or (2) stress (donkeys are more subjected to 
a heavy workload, travel longer distances, are generally in a poor nutritional state, and have 
a heavy parasite burden). In contrast, a significantly higher prevalence of EHV-2 and EHV-
5 were recorded in horses than in donkeys. This is in agreement with previous studies where 
EHV-2 and EHV-5 have predominantly been found in horses (Franchini et al., 1997; Craig 
et al., 2005; Goehring, 2015). However, information regarding infection of donkeys with 
either EHV-2 or EHV-5 is scarce. Borchers et al. (1999) documented that other than horses, 
the Przewalski’s wild horse and the mountain zebras have been identified to be susceptible 
for EHV-2 and EHV-5. This detection of EHV-2 and EHV-5 in donkeys is the first report, 
which provides an important contribution to a better understanding of the epidemiology of 
the disease. At present, a possible explanation why donkeys and horses have a varying 
susceptibility to EHV infection could not be given. 
 
In the present study, a significant variation was not observed among the age groups with 
EHV infections. However, the highest prevalence of EHV-1, -2, -4, and -5 was recorded at 
an age less than three years. This is in line with what has been reported in other studies, 
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where young equids are at greater risk of developing a clinical respiratory disease associated 
with EHV infections (Bell et al., 2006; Carlson et al., 2013; Hue et al., 2014; Gilkerson et 
al., 2015). Young foals are probably infected from their dam by direct contact during the 
first months, after which the virus is transmitted horizontally to in contact foals (Bell et al., 
2006; Brault et al., 2011; Hue et al., 2014).  
 
From the total of 111 clinically healthy equids, EHV-1 and EHV-4 were never detected 
whereas EHV-2 and EHV-5 were recorded from 8 (7.2%) and 18 (16.2%) horses, 
respectively. This detection of EHV-2 and EHV-5 from clinically healthy equids is in 
agreement with previous reports, in which both viruses have been detected from 
immunocompetent equids without signs of respiratory syndromes (Bell et al., 2006; Wang 
et al., 2007; Torfason et al., 2008). Our result supports the statement that presence of EHV-
2 and/or EHV-5 in equids is not sufficient to establish disease causality (Brault and 
MacLachlan, 2011). However, they may compromise host immunity and increase the 
susceptibility of the host to other infections (Nordengrahn et al., 1996; Dunowska et al., 
2002). EHV-2 and EHV-5 were not detected from clinically healthy donkeys. This might be 
due to the small number of donkeys enclosed in this study.  
 
The association of either EHV-2 or EHV-5 detection with the presence of respiratory clinical 
signs was compared between equids displaying signs of respiratory disease and clinically 
healthy equids. A significant difference was not observed between EHV-5-infected equids 
in the respiratory disease group and those not displaying signs of respiratory disease. The 
high prevalence of EHV-5 in clinically normal equids together with the absence of 
significant difference between the respiratory diseased and clinically healthy equids may 
suggest that EHV-5 is unlikely to be involved in clinical respiratory disease in equids. In 
contrast, a significantly higher proportion of EHV-2-infected equids was observed in the 
respiratory disease group compared to those without the disease. EHV-2-positive equids 
were three times more likely to display clinical signs of respiratory disease than EHV-2-
negative equids. This strong association proposes that EHV-2 may play a possible etiological 
contribution either to induce or predispose equids to respiratory diseases. However, further 
studies are needed to better understand the clinical outcome of EHV-2 and EHV-5 infections.  
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The partial sequences of the gB gene of EHV-2 and EHV-5 strains were used to compare 
their phylogenetic relationship with each other and with reference strains from Genbank. 
The phylogenetic analysis of the gB gene showed that EHV-2 and EHV-5 strains detected 
in Ethiopia showed a remarkable genetic diversity. EHV-2 had 94 to 99.4% nucleotide 
sequence identity and 90.2 to 98.3% amino acid sequence identity among each other, 
whereas the degree of similarity with reference strains ranged from 92.9 to 99.1% and from 
87.8 to 98.3% at the level of nucleotide and amino acid sequence, respectively. Similarly, 
the Ethiopian EHV-5 strains showed an overall identity of 95.1 to 100% and 94.7 to 100% 
nucleotide and amino acid level, respectively. Moreover, EHV-5 showed 95.1 to 99.5% 
nucleotide and 94.7 to 98.6% amino acid sequence identity with reference strains from 
GenBank. This high degree of genetic heterogeneity in equine gammaherpesviruses EHV-2 
and EHV-5 is in agreement with previous studies conducted elsewhere (Ataseven et al., 
2010; Bell et al., 2006; Brault et al., 2011; Thorsteinsdóttir et al., 2013). Whether this genetic 
heterogeneity of the gammaherpesviruses has an association with the clinical outcome or not 
is not clear and deserves further investigation.  
 
In conclusion, both equine alphaherpesviruses (EHV-1 and EHV-4) and 
gammaherpesviruses (EHV-2 and EHV-5) are common respiratory tract pathogens in 
donkeys and horses in Ethiopia. EHV-1 and EHV-4 are detected only from equids with 
respiratory diseases, whereas EHV-2 and EHV-5 are detected from both clinically sick and 
clinically healthy equids. The partial sequences of the gB gene of Ethiopian EHV-2 and 
EHV-5 strains have a high degree of genetic heterogeneity. Our results suggest that EHV-2 
is likely to be an important contributor either to induce or predispose equids to respiratory 
diseases. However, more work is needed to better understand the role of EHV-2 in the 
establishment of respiratory disease. 
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Abstract   
 
Replication kinetics and invasion characteristics of equine herpesvirus-1 and -3 (EHV-1/-3) in 
nasal and vaginal mucosae were compared using explants. The explants were cultured during 
96h with little change in viability. The tissues were inoculated with EHV-1 03P37 
(neuropathogenic), 97P70 (abortigenic) and EHV-3 04P57, collected at 0, 24, 48 and 72h post-
inoculation (pi) and stained for viral antigens. Both EHV-1 and EHV-3 replicated in a 
plaquewise manner. The plaques were already observed at 24h pi, their size increased over time 
and did not directly cross the basement membrane. However, EHV-1 infected the monocytic 
cells and hijacked these cells to invade the lamina propria. In contrast, EHV-3 replication was 
fully restricted to epithelial cells; the virus did not breach the basement membrane via a direct 
cell-to-cell spread nor used infected monocytic cells. EHV-1-induced plaques were larger in 
nasal mucosa compared to the vaginal mucosa. The opposite was found for EHV-3-induced 
plaques. Both EHV-1 strains replicated with comparable kinetics in the nasal mucosa. However, 
the extent of replication of the abortigenic strain in vaginal mucosa was significantly higher 
than that of the neuropathogenic strain. Two-to-five-fold lower numbers of EHV-1-infected 
monocytic cells underneath the basement membrane were found in vaginal mucosa than in nasal 
mucosa. Our study has shown that (i) EHV-1 has developed in evolution a predisposition for 
respiratory mucosa and EHV-3 for vaginal mucosa, (ii) abortigenic EHV-1 replicates better in 
vaginal mucosa than neuropathogenic EHV-1 and (iii) EHV-3 demonstrated a strict epithelial 
tropism whereas EHV-1 in addition hijacked monocytic cells to invade the lamina propria.  
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Introduction 
 
Equine herpesvirus 1 (EHV-1) and equine herpesvirus 3 (EHV-3) cause contagious diseases in 
equids worldwide (Allen and Umphenour, 2004; Allen et al., 2004). EHV-1 is responsible for 
respiratory disorders, abortion, neonatal foal death, myeloencephalopathy or chorioretinopathy 
(Allen et al., 2004; Hussey et al., 2013). EHV-3 is the cause of equine coital exanthema (ECE), 
a genital disease that is transmitted venereally. This disease is characterized by the development 
of papules, vesicles, pustules and ulcers in the mucosa of the vagina and vestibule of mares and 
the penis and prepuce of stallions, in the skin of the perineal region of the mares and 
occasionally on the skin of the lips and mucosa of the upper respiratory tract (Allen and 
Umphenour, 2004; Barrandeguy et al., 2010b; Kleiboeker and Chapman, 2004). Both EHV-1 
and EHV-3 are members of the subfamily Alphaherpesvirinae with about 150 kilobases double-
stranded DNA genome, consisting of 76 unique open reading frames (Sijmons et al., 2014; 
Telford et al., 1992). However, antigenically, genetically and pathogenetically, EHV-1 and 
EHV-3 are significantly different (Allen and Umphenour, 2004). 
 
Latently infected equines are important biological reservoirs for EHV-1 (Slater et al., 1994; 
Carvalho et al., 2000) and EHV-3 (Allen and Umphenour, 2004; Barrandeguy et al., 2008). The 
periodic virus reactivation from latency leads to the production of infectious virus that serves 
as a source of infection (Allen et al., 2004; Barrandeguy et al., 2008). EHV-1 is transmitted to 
susceptible equids through direct contact with virus-laden respiratory secretions or indirectly 
with fomites (Allen et al., 2004). Although EHV-3 is primarily transmitted through coitus, 
contaminated fomites have also been implicated in its spread (Metcalf, 2001).  
 
After initial infection, EHV-1 replicates in mucosal epithelial cells of the upper respiratory tract 
and causes erosions and viral shedding into the environment (Allen et al., 2004; Kydd et al., 
1994a). The virus then invades the underlying lamina propria by infected immune cells 
(Gryspeerdt et al., 2010; Kydd et al., 1994a, 1994b). Hereafter, EHV-1 disseminates throughout 
the body using infected mononuclear cells as Trojan horses (Laval et al., 2014). The cell-
associated viremia allows the virus to arrive and replicate in the endothelial cells of the target 
organs, which leads to vasculitis and ischemic thrombosis (Edington et al., 1986). In contrast, 
EHV-3 replicates in the stratified epithelium of epidermal tissues present at the mucocutaneous 
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margins and skin (Allen and Umphenour, 2004). Destruction of the epithelium by the lytic virus 
infection elicits a vigorous, localized inflammatory response that gives rise to the formation of 
characteristic cutaneous lesions of ECE (Allen and Umphenour, 2004). Infertility and abortion 
associated with EHV-3 have not been reported (Pascoe, 1981; Van der Meulen et al., 2006). 
However, the disease has a negative impact in the equine industry as a result of the forced, 
temporary disruption of the mating activities of affected stallions and mares (Allen and 
Umphenour, 2004; Barrandeguy and Thiry, 2012).  
 
Different strains of EHV-1 have a different pathological outcome, which is correlated with the 
variation in the ability to disseminate and establish infection in vascular endothelial cells of the 
target organs such as the endometrium, the central nervous system and the eye (Patel et al., 
1982; Hussey et al., 2013). The respiratory mucosal surface plays a major role in EHV-1 
primary replication and transmission (Kydd et al., 1994b). Variation in the structural barriers, 
microenvironment and the composition of available target cells on mucosal tissues may 
dramatically influence the efficiency of EHV-1 replication. Previous studies have shown the 
invasion mechanisms of EHV-1 in the equine respiratory mucosa using nasal explants 
(Vandekerckhove et al., 2010) and an in vivo experiment (Gryspeerdt et al., 2010). It was 
demonstrated that during infection of epithelial cells, EHV-1 is infecting mucosal monocytes 
and is hijacking these cells to invade the deeper connective tissues. Despite these studies, little 
is known about the replication efficiency of EHV-1 strains in the vaginal epithelial mucosa, 
which could serve as an alternative EHV-1 portal of entry. 
 
EHV-3 is highly host specific. It replicates only in cell lines derived from equids and a 
laboratory animal model has not been identified for EHV-3 infection (Allen and Umphenour, 
2004; Barrandeguy et al., 2012). To date, experimental studies with EHV-3 have solely been 
done in the natural hosts, equids. To study early events of EHV-3 mucosal invasion, an 
alternative in vitro model would be very valuable. Previously, the replication characteristics of 
other equine alphaherpesviruses, EHV-1 and EHV-4, have been studied in respiratory mucosa 
explants (Vandekerckhove et al., 2011, 2010). The replication of EHV-4 was restricted to the 
epithelial cells, whereas EHV-1 was also infecting mucosal leukocytes. However, the 
replication kinetics and the invasion characteristics of EHV-3 in mucosae are still not known.  
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Therefore, this study was designed to compare the replication kinetics and the invasion 
characteristics of the neuropathogenic and abortigenic strains of EHV-1 and EHV-3 in the nasal 
and vaginal mucosae using ex vivo tissue cultures. 
 
Materials and methods 
 
Tissue collection 
The nasal and vaginal tissues were obtained from healthy horses after slaughter in the abattoir. 
Tissues were taken from three female horses with an estimated age of 5 - 10 years. The absence 
of recent EHV-1 and EHV-3 infection was demonstrated by the absence of cytopathic effect 
upon inoculation of rabbit kidney 13 cell and equine dermal cell lines with tissue suspensions 
(10% W/V). The stage of the reproductive cycle was also evaluated by visual inspection of the 
ovaries. All the animals were found to be in diestrus.  
 
All the tissues were collected in transport medium containing phosphate buffered saline (PBS) 
supplemented with 1μg/ml gentamycin (Invitrogen, Paisley, UK), 1 mg/ml streptomycin (Certa, 
Braine l’Alleud, Belgium), 1 mg/ml kanamycin (Sigma, St. Louis, MO, USA), 1000 U/ml 
penicillin (Continental Pharma, Puurs, Belgium) and 5 μg/ml amphotericin B (Bristol-Myers 
Squibb, New York, USA). All collected tissues were placed in a cooler containing ice for 
transport to the laboratory and were processed immediately after arrival. The mucosae were 
stripped from the underlying tissues and dissected into explants of approximately 25 mm2.  
 
Air-liquid culture model 
Cultivation of the explants was performed according to the protocol as previously described 
(Vandekerckhove et al., 2009; Steukers et al., 2011) with some modifications. Briefly, the 
explants were cultured using fine-meshed gauze, on 6-well tissue culture plate, in an air-liquid 
interface with epithelium facing upwards. The explants were cultured with serum-free medium 
consisting of a 1:1 mixture of Roswell Park Memorial Institute medium (RPMI GlutaMAX™) 
(Invitrogen) and Dulbecco's Modified Eagle’s Medium (DMEM GlutaMAX™) (Invitrogen) 
supplemented with 1μg/ml gentamycin (Invitrogen), 0.1mg/ml streptomycin (Certa, Braine 
l'Alleud, Belgium) and 100U/ml penicillin (Continental Pharma, Puurs, Belgium). To mimic an 
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air-liquid interface as in the living animal, the explants were covered with a thin-film of medium 
and maintained at 37°C in an atmosphere containing 5% CO2.  
 
Evaluation of tissue viability 
Tissue viability was monitored by evaluating ciliary beating of the epithelial cells of the nasal 
explants using a light microscope and by quantifying the apoptotic cells using in situ cell death 
detection kit (Roche Diagnostics Corporation, Basel, Switzerland). Terminal deoxynucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL), preferentially labels DNA strand 
breaks generated during apoptosis. The test was performed according to the manufacturer's 
guidelines on cryosections preserved in methocel® (Sigma) at 0, 24, 48, 72 and 96h of 
cultivation. In both the epithelium and lamina propria, the percentage of TUNEL-positive cells 
was quantified in five randomly chosen fields of 100 cells each. TUNEL-positive cells were 
detected and enumerated by fluorescence microscopy (Leica DMRBE, Wild Leitz GmbH, 
Heidelberg, Germany). 
 
Virus strains used for infections of the explants  
Two Belgian EHV-1 strains, representing neuropathogenic and abortigenic variants of EHV-1, 
were used in this study. These strains were typed by sequencing the DNA polymerase gene of 
EHV-1 as previously described (Nugent et al., 2006). The abortigenic EHV-1 strain 97P70 
which was isolated from an aborted fetus in 1997 and the neuropathogenic strain 03P37 which 
was isolated from the peripheral blood mononuclear cells of paralytic horses in 2003, were 
used. EHV-1 virus stocks used for inoculation of the explants were at the 6th passage; 4 passages 
in equine embryonic lung cells and 2 subsequent passages in rabbit kidney 13 cells.  
 
The EHV-3 strain 04P57 which was isolated from a horse with typical ECE lesions in Belgium 
in 2004, was used in this experiment. The virus stock used for inoculation was at the second 
passage in equine embryonic kidney cells. Genetic and pathogenic differences between EHV-
3 strains have not been described and therefore, only one EHV-3 strain was included in this 
study. 
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Inoculation of the explants  
After 24h of culture, explants were inoculated with the strains of EHV-1 and EHV-3 by 
submerging the tissue in 1ml of inoculum containing 106.5 TCID50 for 1h at 37
oC and 5% CO2. 
After incubation, explants were washed twice with warm medium and transferred back to the 
original 6-well plates containing gauze and medium. At 0, 24, 48 and 72h post-inoculation (pi), 
explants were collected, embedded in methylcellulose medium (Methocel® MC, Sigma-
Aldrich, St. Louis) and frozen at -70°C.  
 
Immunofluorescence staining and plaque analysis 
A double immunofluorescence staining was performed to detect and localize EHV-1 and EHV-
3-infected cells at 0, 24, 48 and 72h pi in 100 consecutive 16µm cryosections of the explants. 
The cryosections were fixed with 100% methanol for 20 min at -20oC. The basement membrane 
(BM) of the tissues was stained with monoclonal mouse anti-collagen VII antibodies (Sigma-
Aldrich, St. Louis), followed by Texas red-labeled goat anti-mouse antibody (Invitrogen). 
Biotinylated equine polyclonal anti-EHV-1 IgG antibodies (Van der Meulen et al., 2000) were 
used to label the EHV-1 viral antigens and biotinylated rabbit polyclonal anti-EHV-3 IgG 
antibodies to label EHV-3 viral antigens. Next, fluorescein isothiocyanate (FITC) labeled 
streptavidin (Invitrogen) was added. Mock-inoculated cryosections were stained as negative 
controls. In each step, cryosections were incubated at 37oC for 1h and were washed afterward 
three times with PBS. Hoechst 33342® staining (molecular probes) was performed to visualize 
the nuclei of the cells. Then, the cryosections were mounted with glycerol containing antifading 
agent 1, 4-Diazobicyclo-(2, 2, 2-octane (DABCO®). The plaques were visualized using a 
confocal fluorescence microscope (Leica DMRBE, Wild Leitz GmbH, Heidelberg, Germany). 
The number of plaques per 8mm2 explants and the plaques size was quantified using Leica LAS 
AF Lite software. The plaques on the borders and edge of the explants were excluded from 
analysis. 
 
Identification and quantification of single infected cells 
To identify and quantify EHV-1 and EHV-3 infected single cells, a double immunofluorescence 
staining was performed. At each collection time point, 10μm-thick cryosections of tissue 
explants were fixed in 100% methanol at -20°C for 20min. For each tissue and each time point, 
20 cryosections were stained for each cell surface marker separately. Monoclonal antibodies 
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DH59B (VMRD, USA), UC F6G-3 (California University, Davis, USA) and 1.9/3.2 (VMRD, 
USA) were used as markers for CD172a cells of the monocyte lineage, CD3 cells (pan T-
lymphocytes) and IgM cells (B-lymphocytes), respectively. Then, the cryosections were 
incubated with Texas Red®-labeled goat anti-mouse IgG antibodies (Invitrogen). In the second 
step, EHV-1 and EHV-3 viral proteins were stained with biotinylated equine polyclonal anti-
EHV-1 IgG antibodies (Van der Meulen et al., 2000) and biotinylated rabbit polyclonal anti-
EHV-3 IgG antibodies, respectively, followed by streptavidin-FITC (Invitrogen). Sections of 
mock-inoculated explants and isotype-matched irrelevant control antibodies were used as 
negative controls. In each step, cryosections were incubated at 37oC for 1h and washed three 
times with PBS. The nuclei were counterstained with Hoechst 33342® for 10min. At each time 
point, the percentage of EHV-1 infected cells that are marker-positive cells were calculated 
from 20 cryosections of 10µm thick for each specific marker. All the cryosections were 
analyzed by confocal microscopy (Leica DMRBE, Wild Leitz GmbH, Heidelberg, Germany).  
 
Statistical analysis 
The data were analyzed using SPSS version 20 software (SPSS Inc, Chicago, USA). 
Differences between the strains, tissues and among time points were compared by the analysis 
of variance (ANOVA) with post hoc multiple comparisons. Mann-Whitney test was also used 
as a non-parametric test. All data are expressed as means with standard deviation (SD) of three 
independent experiments. Differences were considered statistically significant when P-value 
was < 0.05. 
 
 
Results 
 
Tissue viability  
The viability of the cells in the nasal and vaginal explants was evaluated using TUNEL staining 
to detect DNA fragmentation associated with apoptotic cell death at 0, 24, 48, 72 and 96h of 
cultivation. During the ex vivo tissue cultivation, the number of apoptotic cells in the epithelium 
slightly, but not significantly, increased over time. The percentage of TUNEL-positive cells in 
the epithelium of the nasal and vaginal mucosae was 1.7±0.2 and 1.9 ± 0.1, respectively, at 96h 
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of cultivation (Table 1). In the epithelium of the nasal mucosa, the ciliary beating was observed 
during the whole experiment (up to 96h of cultivation). 
 
Table 1: Percentage of TUNEL-positive cells in the epithelium and lamina propria of the nasal 
and vaginal mucosae at different time points of cultivation. 
 
 
Percentage of TUNEL-positive cells at indicated time points of cultivation 
0h 24h 48h 72h 96h 
Nasal mucosa     
 Epithelium 0.3±0.1 0.4±0.2 0.7±0.1 1.3±0.1 1.7±0.2 
 Lamina propria 0.7±0.1 1.1±0.3 2.5±0.3 3.1±0.2 4.2±0.2 
Vaginal mucosa      
 Epithelium 0.4±0.2 0.7±0.1 1.4±0.3 1.7±0.1 1.9±0.1 
 Lamina propria 0.9±0.2 1.3±0.4 3.4±0.5 3.6±0.6 6.2±0.4 
 
Invasion characteristics 
The invasion characteristics of EHV-1 and EHV-3 were assessed in the nasal and vaginal 
mucosae at 0, 24, 48 and 72h pi. In mock-infected explants, plaques were not observed 
throughout the experiments. Both strains of EHV-l and EHV-3 replicated in a plaquewise 
manner and spread laterally in the epithelium. The plaques in the epithelium were already found 
at 24h pi, their sizes significantly increased over time and they did not cross the BM at all the 
time points pi. However, EHV-1 and EHV-3 exhibited different invasion characteristics. EHV-
1 infects mononuclear immune cells to invade the lamina propria (Figure 1). In contrast, EHV-
3 replication was restricted to the epithelium of the nasal and vaginal mucosae, where the virus 
neither breaches the BM nor infects individual monocytic immune cells at all time points pi 
(Figure 2). 
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Nasal mucosa 
 
                 
                 
 
Vaginal mucosa  
 
                 
                 
 
Figure 1: Confocal photomicrographs showing EHV-1-induced plaques in nasal and vaginal 
explants inoculated with EHV-1 03P37 and EHV-1 97P70. The BM is visualized using mouse 
anti-collagen VII and goat anti-mouse Texas Red® antibodies. The viral antigens are detected 
0h 24h
rs 
48h 72h 
24h 
03P37 
0h 
97P70 
97P70 
03P37 
0h 24h 48h 72h 
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using biotinylated equine polyclonal anti-EHV-1 IgG antibodies and striptavidin-FITC®. Scale 
bar: 100µm. 
 
 
         
 
 
         
  
Figure 2: Confocal photomicrographs showing EHV-3-induced plaques in the nasal and 
vaginal mucosa infected with EHV-3 04P57. The BM is visualized using mouse anti-collagen 
VII and goat anti-mouse Texas Red® antibodies. The viral antigens are detected using 
biotinylated rabbit polyclonal anti-EHV-3 IgG antibodies and streptavidin-FITC®. Scale bar: 
100µm. 
 
Number of plaques 
The number of plaques induced by EHV-1 and EHV-3 on 8mm2 of explants was counted at 24, 
48 and 72h pi. In both mucosae, the average number of plaques induced by both strains of EHV-
1 significantly increased (P < 0.05) over time. In the nasal mucosa, no significant difference (P 
> 0.05) was observed in the average number of plaques between both EHV-1 strains (Figure 3). 
However, the average number of plaques in the vaginal mucosa was significantly higher (P < 
0h 
72h 
72h 24h 48h 
Vaginal mucosa 
0h 24h 48h 72h 
Nasal mucosa 
Replication characteristics of EHV-1 and EHV-3  
106 
0.05) with the abortigenic strain 97P70 compared to the neuropathogenic strain 03P37 at all 
time points pi. Overall, the average number of plaques counted in the nasal mucosa was 
significantly higher (P < 0.05) than in the vaginal mucosa.   
 
With EHV-3, the average number of plaques in the nasal mucosa slightly, but not significantly 
(P > 0.05) increased over time. However, the average number of plaques in the vaginal mucosa 
significantly increased (P < 0.05) between 24 and 72h pi. Overall, the average number of 
plaques was significantly higher (P < 0.05) in the vaginal mucosa than in the nasal mucosa at 
24 and 72h pi (Figure 3).  
 
Plaques size 
Both strains of EHV-1 had a different potential to spread from cell-to-cell in the nasal and 
vaginal mucosae. In the nasal mucosa, the neuropathogenic EHV-1-induced plaques enlarged 
significantly (P < 0.05) over time with an average of 77.9±22.1 µm at 24h pi, 140.1±45.0 µm 
at 48h pi and 216.1±44.9 µm at 72h pi. Likewise, the size of the plaques induced by the 
abortigenic strain significantly (P < 0.05) increased over time with an average of 68.9±15.8 µm 
at 24h pi, 166.9±52.3 µm at 48h pi and 245.5±52.3 µm at 72h pi. However, the average sizes 
of the plaques were not significantly different (P > 0.05) between both EHV-1 pathotypes 
(Figure 3). In the vaginal explants, the size of the plaques induced by the abortigenic strain 
significantly increased (P < 0.05) between 48 and 72h pi with an average of 125±41.7 µm and 
192±89.5 µm, respectively. Similarly, the plaque size slightly, but not significantly (P > 0.05) 
increased over time with the neuropathogenic strain. In contrast, the average size of the plaques 
induced by the neuropathogenic strain was significantly smaller (P < 0.05) when compared to 
the abortigenic strain at all time points pi (Figure 3). 
 
Overall, the average sizes of the plaques induced by both EHV-1 strains were significantly 
larger (P < 0.05) in the nasal mucosa than in the vaginal mucosa. 
 
With EHV-3, the average size of the plaques significantly increased (p < 0.05) over time in both 
the nasal and vaginal explants. The average size of EHV-3-induced plaques in the vaginal 
mucosa was 56.5±20.1 µm, 84.5±33.8 µm, and 149.2±53.0 µm at 24, 48 and 72h pi, 
respectively. Similarly, an average of 35.7±12.5 µm (24h pi), 59.6±9.1 µm (48h pi) and 
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100.8±41.5 µm (72h pi) plaque size was recorded in the nasal mucosa. Overall, the average size 
of the plaques induced by EHV-3 was significantly higher (P < 0.05) in the vaginal mucosa, 
compared to the nasal mucosa at all time points pi (Figure 3). 
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Figure 3: Replication kinetics of EHV-1 (A and B) and EHV-3 (C) in the nasal and vaginal 
explants. The number of plaques/8mm2 explants and the plaque size are shown. Data represent 
means ± SD of triplicate independent experiments. Significant differences are indicated by the 
use of different letters.  
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Identification and quantification of single infected cells 
Single EHV-1 and EHV-3-infected cells underneath the BM of the nasal and vaginal mucosa 
tissues were assessed. In both mucosal tissues, EHV-3-infected cells underneath the BM were 
totally not detected at all the time points pi. In both mucosae, EHV-1-infected cells were already 
visible starting from 24h pi with the neuropathogenic strain and from 48h with the abortigenic 
strain (Figure 4). 
 
 
  
 
 
 
Figure 4: Representative confocal microscope images of marker positive-EHV-1-infected cells 
in the vaginal mucosa. The explants were sectioned (10µm) and co-immunostained for EHV-1 
infected cells (green) and marker-positive cells (red). The white dotted line indicates the BM. 
White arrowheads show double positive cells.  
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The percentage of abortigenic EHV-1-infected individual monocytic cells was two-fold lower 
in the vaginal mucosa than in the nasal mucosa. Similarly, up to a five-fold lower percentage 
of neuropathogenic EHV-1-infected individual monocytic cells was recorded in the vaginal 
mucosa than in the nasal mucosa. Regardless of the tissues and strains of EHV-1, CD172a+ 
cells from the monocytic lineage were the predominant cells type infected, followed by CD3+ 
T-lymphocytes. EHV-1 infects IgM+ cells (B-lymphocytes) to a much lesser extent (Figure 5). 
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Figure 5: Percentage of EHV-1-infected individual cells. The cells were identified as 
monocytic cells (CD172a+), pan T-lymphocytes (CD3+) and B-lymphocytes (IgM+) per 20 
sections of the nasal and vaginal mucosal explant infected with EHV-1 03P37 (A) and EHV-1 
97P70 (B). Lines show the means ± SD of three independent experiments.  
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Discussion 
 
Neuropathogenic and abortigenic EHV-1 strains, that display different diseases are circulating 
in the field. The mucosal surface of the upper respiratory tract plays a major role in EHV-1 
replication and transmission. Despite several studies conducted on the replication kinetics and 
characteristics of EHV-1 on the tissues of the upper respiratory tract, the replication efficiency 
of both pathotypes in the vaginal mucosa was never studied before. EHV-3 has been associated 
with both genital and respiratory diseases, however, the underlying pathogenesis remains 
poorly understood, due in part to the lack of appropriate models to study virus-host interactions. 
Therefore, in this study, ex vivo respiratory and vaginal mucosa explant cultures were developed 
to gain more insight into the replication kinetics and invasion characteristics of the 
neuropathogenic and abortigenic strains of EHV-1 and to elucidate the pathogenesis of EHV-3 
in the nasal and vaginal mucosae, target organs for virus entry and replication. The explants, 
directly derived from the upper respiratory tract and the vagina of the horses, were maintained 
in an air-liquid interface for up to 96h with little change in the viability of the cells as evaluated 
by ciliary beating and the number of apoptotic cells. The mucosal explant models showed an 
intact 3-dimensional structure and contained all resident mucosal target cells and consequently 
are ideal to study the virus-host interactions at the site of infection. These explants from 
slaughterhouse horses replace experimental animals and, as such, are in line with the 3Rs of 
animal welfare. 
 
In the present study, both types of EHV-l and EHV-3 replicated in a plaquewise manner and 
spread laterally on the epithelium. The plaques were already present on the epithelium starting 
from 24h pi and their sizes significantly increased over time. The plaques did not cross the BM 
to infect the underlying tissues at all time points pi. However, the invasion via single infected 
leukocytes in the underlying connective tissue was different. EHV-1 breached the BM and 
invaded the lamina propria using infected mononuclear immune cells. In contrast, EHV-3 
replication was restricted to the epithelial cells, where the virus neither breached the BM in a 
direct way nor infected individual immune cells to invade the lamina propria. This non-invasive 
behavior of EHV-3 is comparable with what has been seen for EHV-4 (Vandekerckhove et al., 
2011), but is in contrast with other members of alphaherpesviruses such as pseudorabies virus 
(PRV) (Glorieux et al., 2009), bovine herpesvirus 1 (BoHV-1) (Steukers et al., 2011), herpes 
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simplex virus 1 (HSV-1) (Glorieux et al., 2011a), canine herpesvirus 1 (CaHV-1) (Li et al., 
2016), feline herpesvirus 1 (FeHV-1) (Li et al., 2015) and  infectious laryngotracheitis virus 
(ILTV) (Reddy et al., 2014), which breach the BM and infect the underlying connective tissue. 
For PRV, it was shown that a cellular serine protease is responsible for this phenomenon 
(Glorieux et al., 2011b). 
 
In our study, both strains of EHV-1 types have remarkably higher replication kinetics in the 
nasal mucosa compared to the vaginal mucosa as evaluated by the number of plaques counted, 
the size of the plaques, and the amount of infected individual mononuclear immune cells. This 
suggests that the nasal mucosa is the primary tissue of preference for EHV-1 replication and 
entry into its host. Both EHV-1 types replicated with comparable kinetics in the nasal mucosa 
at all time points pi. This result is consistent with the earlier report in the respiratory mucosa 
explants study (Vandekerckhove et al., 2010), where no differences were observed in the 
replication kinetics between both EHV-1 types. Despite the fact that EHV-1 has a main tropism 
for the respiratory mucosa, the vaginal mucosa is able to support replication. However, the 
magnitude of replication in the vaginal mucosa was significantly different between the two 
EHV-1 strains. The neuropathogenic strain replicated less efficiently than the abortigenic strain 
and at 72h pi a lot of non-infected basal cells were observed between the cluster of infected 
epithelial cells and the BM for the neuropathogenic strain but not for the abortigenic strain. 
Several reasons may be responsible for this observation. Gryspeerdt et al. (2010) reported that 
after three days of infection the production of interferon limits EHV-1 replication in the 
epithelium of the upper respiratory tract. Maybe the same defense mechanism is activated in 
the vaginal mucosa. EHV-1 infection induces high antiviral interferon-α levels, which is critical 
in the host innate immune response (Wagner et al., 2011). Another possible explanation for the 
difference in replication efficiency observed between the two EHV-1 strains might be 
associated with viral genetic factors. Goodman et al., (2007) reported that EHV-1 virulence and 
tissue tropism in the natural host are linked with the function of the DNA polymerase. Indeed, 
a single point mutation in this enzyme has been claimed to be responsible for the neurotropism. 
It would now be very interesting to determine if the same point mutation in this enzyme is also 
determining the level of EHV-1 replication in the vaginal mucosa. It is very well possible that 
this point mutation is generally affecting the replication of EHV-1 in the different mucosae of 
the genital tracts (endometrium and vaginal mucosa). 
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In this study, although we clearly demonstrated that both EHV-1 types are capable of replicating 
in the mucosa of the vaginal epithelium, the extent of replication is much higher with the 
abortigenic strain compared with the neuropathogenic strain. Previous reports indicated that 
EHV-1 has been isolated from male genital organs (Tearle et al., 1996) and is shed with the 
semen and the sperm cells (Fritsche and Borchers, 2011; Hebia-Fellah et al., 2009; Walter et 
al., 2012). When we combine the latter reports with our findings, we could propose a possible 
venereal transmission of EHV-1 via the semen, which was largely ignored before. The venereal 
transmission has been well documented for other alphaherpesviruses such as EHV-3 (Allen and 
Umphenour, 2004), BoHV-1 (Wrathall et al., 2006; Bielanski et al., 2014), PRV (Romero et 
al., 2001) and CaHV-1 (Evermann et al., 2011). Therefore, our study highlights an important 
insight that should be further investigated in the field.  
 
In our study, although both the nasal and vaginal mucosae were infected by EHV-3, the 
replication kinetics are significantly different. The sizes of EHV-3-induced plaques are 
significantly larger in the vaginal mucosa than the nasal mucosa. This replication advantage of 
EHV-3 in the vaginal mucosa might be associated with the virus tissue tropism, as it has a 
higher affinity to affect the genital organs under natural conditions. Although, post-coital 
infection of the EHV-3 is the general route of transmission, non-venereal transmission to the 
nasal mucosa has been reported via genitonasal contact and contaminated objects (Allen and 
Umphenour, 2004; Barrandeguy et al., 2010a). In the current study, EHV-3 replication was 
restricted to the epithelium mucosae, where the virus neither breached the BM to invade the 
lamina propria nor infected individual mononuclear immune cells. This localized replication 
behavior might limit the EHV-3 dissemination via systemic blood circulation. In vivo EHV-3 
infection destroys the epithelium and elicits a vigorous, localized inflammatory response (Allen 
and Umphenour, 2004) and systemic dissemination of the virus is exceptional (Barrandeguy et 
al., 2010a). Whether host factors or viral factors inhibit the virus to infect individual immune 
cells and to invade the underlying tissue is not clear and deserves further investigation.  
 
In the current study, the neuropathogenic strain infects a higher percentage of monocytic cells 
in the nasal mucosa when compared to the abortigenic strain. This result is in line with the 
previous report made by Vandekerckhove et al. (2010) in the nasal explants study and 
Gryspeerdt et al. (2010) in an in vivo study. However, the neuropathogenic strain infects a lower 
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percentage of cells in the vaginal mucosa than the abortigenic strain of EHV-1. These results 
suggest that the number of single infected cells may vary with the mucosa type infected with 
EHV-1. With both EHV-1 types, two-to-five-fold lower percentage of infected monocytic cells 
were found in the lamina propria of the vaginal mucosa than in that of the nasal mucosa. 
Infected individual cells underneath the BM were visible already at 24h pi with the 
neuropathogenic strain, and at 48h pi with the abortigenic strain. The monocytic lineage cells, 
which express surface marker CD172a, were the predominant cell type infected with EHV-1, 
independent of the strain and tissue. This is in agreement with the previous report in the nasal 
explants (Vandekerckhove et al., 2010), in an in vivo experiment (Gryspeerdt et al., 2010), and 
in peripheral blood mononuclear cells (Baghi and Nauwynck, 2014; Laval et al., 2014). This 
cell marker is expressed in equine monocytes, macrophages, dendritic cells and granulocytes 
(Van Beek et al., 2005; Barclay and Brown, 2006). Recently, Baghi et al. (2014) reported that 
isolated equine nasal mucosal CD172a+ cells resemble immature dendritic cells. The dendritic 
cells in the periphery capture and process antigens, express lymphocyte co-stimulatory 
molecules, migrate to lymphoid organs and secrete cytokines to initiate immune responses 
(Banchereau and Steinman, 1998). CD3+ T- lymphocytes were also an important cell type 
infected with EHV-1. IgM+ cells (B- lymphocytes) were infected to a much lesser extent. 
 
In conclusion, EHV-1 and EHV-3 exhibited different invasion characteristics. Both viruses 
replicated in a plaquewise manner and spread laterally on the epithelium. EHV-3-induced 
plaques are restricted to the epithelium of the nasal and vaginal mucosae and the virus neither 
breaches the BM nor infect individual immune cells at all time points pi. In contrast, EHV-1 
invades the underlying connective tissue by infecting mononuclear immune cells. Our ex vivo 
explant models provided an important new insight that should be further investigated in order 
to better understand the underlying mechanisms and in vivo relevance. 
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EHV-1 is an important pathogen, causing an array of disorders including respiratory disease in 
young horses, abortion in pregnant mares, neonatal foal death, myeloencephalopathy, or 
chorioretinopathy (Allen et al., 2004; Hussey et al., 2013). The main relevant epidemiological 
feature of EHV-1 is a high incidence of respiratory infection early in life, the establishment of 
a life-long latent infection in a high percentage of equids, and periodic reactivation of latent 
virus with subsequent shedding, resulting in horizontal transmission to naive hosts (Allen et al., 
2004). Currently, available vaccines do not reliably prevent infection, development of viremia 
or establishment of latency, and EHM has been reported in horses regularly vaccinated against 
EHV-1 within 3-5 month intervals (Friday et al., 2000; Henninger et al., 2007). Thus, early 
recognition of the disease is very crucial for the implementation of management practices that 
decrease the risk of exposure of susceptible equids. Several epidemiological studies have been 
conducted on equine herpesviruses, however, many data gaps exist and more investigation 
needs to be done to better understand the epidemiology of the disease in the different 
geographical settings and equine populations. Epidemiological investigations of EHV 
outbreaks, particularly in unvaccinated populations, are very important to improve our 
understanding of herpesvirus pathogenesis. The analysis of this epidemiological data is also 
very crucial in order to design more effective intervention strategies. Therefore, in chapter 3 
of this thesis, the epidemiology of EHVs in Ethiopian equids was addressed.  
 
Equine herpesvirus 1 myeloencephalopathy outbreaks in Ethiopian equids 
 
In the first study (chapter 3.1) of this thesis, we described the occurrence of EHM outbreaks in 
horses, mules, and donkeys in Ethiopia. During the period of 2011 to 2013, we recorded 14 
EHM outbreaks in 10 districts of the country. We described EHV-1-associated outbreaks that 
occurred for the first time in Ethiopian equids. We found a large number of clinically affected 
donkeys, besides horses and mules and an increasing frequency of EHM-associated outbreaks 
over time. Moreover, we observed an EHM spread at an alarming rate to different parts of 
Ethiopia. Based on this knowledge, EHM is considered as an emerging threat to Ethiopian 
equids. EHM has been described for many years, but in recent years, there has been an apparent 
increase in frequency and severity in most parts of the world. In 2007, the US Department of 
Agriculture, the Center for Emerging Issues released an emerging disease notice report 
regarding the neurologic form of EHV-1 (USDA-APHIS, 2007). 
 Chapter 5 
121 
In this thesis, we described the clinical signs associated with EHM infection in Ethiopian equids 
and visible differences in the clinical presentation of EHM among horses, mules, and donkeys 
were not observed. However, we found large numbers and more severe EHM-associated 
clinical signs in donkeys within the population. We noticed that donkeys were frequently found 
dead associated with EHM after showing ataxia and paresis, but without demonstrating clinical 
signs of complete paralysis and recumbency. In previous studies, donkeys and mules were 
considered as a silent reservoir host of EHV-1 infections (Van Maanen, 2002; Pusterla et al., 
2012). This clinical outcome of EHV-1 infections in Ethiopian equids might be associated with 
(1) the host factor, where the Ethiopian donkeys might be highly susceptible to EHM infection, 
(2) the stress factors, where equids are subjected to heavy workload, traveling long distances, 
poor nutritional state, heavy parasite burden, and concurrent diseases, or (3) a difference in the 
pathogenic potential of EHV-1 strains. Barbic et al. (2012) and Goehring (2015a) observed a 
significant influence of breed on the clinical outcome of neuropathogenic EHV-1 infections. 
Based on the relatively fast course and fatal nature of EHV-1 infection in donkeys, it is worth 
studying the pathogenesis of EHM in donkeys both in vivo (ex vivo) and in vitro. 
  
Together with the well-known association of genotype and differences in clinical signs, the 
season of the year, age, and gender have been reported as risk factors associated with EHV-1 
infection (Goehring et al., 2006; Lunn et al., 2009). In our study, we recorded outbreaks of 
EHM during all seasons of the year, but a higher incidence of EHM was observed from April 
till mid-June. Strong seasonal clustering of EHM outbreaks has been described in The 
Netherlands (Goehring et al., 2006), where most outbreaks occurred between mid-November 
and mid-May. This seasonal clustering of EHM outbreaks was mainly associated with close 
confinement of equids (Goehring et al., 2006; Lunn et al., 2009). However, in Ethiopia, this 
temporal clustering of EHM outbreaks might be mainly due to stress associated with 
insufficient feed availability during these months of the year. Further, we observed EHM-
affected equids mainly over 3 years of age and equids within the age ranged from 7-10 years 
were mostly affected. It has been reported in previous studies that adult horses were at a greater 
risk for developing EHM than young horses (Goehring et al., 2006; Barbic et al., 2012; Pusterla 
and Hussey, 2014). Although we clearly demonstrated that clinical EHM was largely restricted 
to equids over three years of age, the association of clinical manifestation of EHM and 
immunity remains to be determined. Mumford et al., (1987) isolated EHV-1 from the 
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nasopharynx of apparently healthy foals at the age of 7 - 9 days with high titers of maternal 
colostral antibody, during an abortion storm. This indicates that transfer of maternal virus 
neutralizing antibodies could not prevent infection, at least of the upper respiratory tract, but 
could provide clinical protection (Kydd et al., 2006).  
 
The molecular epidemiological studies of EHV-1 have demonstrated that EHM is significantly 
associated with a SNP resulting in an amino acid variation of the EHV-1 DNA polymerase gene 
(ORF30) (Nugent et al., 2006; Goodman et al., 2007; Van de Walle et al., 2009). EHV-1 
encoding aspartic acid (D752) at amino acid position 752 has significantly a higher risk of 
causing neurological disease than those with the asparagine (N752) (Nugent et al., 2006). In this 
thesis, we reported that 98.9% (90 out of 91) of equids with clinical signs of EHM were infected 
with ORF30 D752 variants, which indicated that the neuropathogenic variants were the 
predominant EHV-1 strains circulating in Ethiopian equids. It has been reported that more than 
86% of EHM outbreaks are associated with strains encoding D752 (Nugent et al., 2006), whereas 
N752 variants have been responsible for approximately 95-98% of abortion outbreaks and 
between 15-25% of neurological outbreaks in the US, the UK, and other countries (Lunn et al., 
2009). We also performed a phylogenetic analysis of ORF68 gene of EHV-1 isolates from 
Ethiopian equids. ORF68 has been described as a marker for strain variability that has shown 
some geographic restriction (Nugent et al., 2006) and helps to trace the source of the EHV-1 
disease outbreaks (Barbic et al., 2012). In this study, we found that all the Ethiopian EHV-1 
isolates belong to geographical group four. This group was mostly represented by the American 
and European EHV-1 isolates. In Ethiopia, there was no importation of equids from other 
countries and thus, it is very difficult to trace the origin of EHM outbreaks, leading the current 
problems. 
 
Prevention of EHV-1 is difficult because many equids are latently infected, allowing the virus 
to circulate silently in equine populations, and the currently available modified live and 
inactivated vaccines are not reliably protective against the severe manifestations of the disease, 
including the fatal myeloencephalopathy. However, vaccination significantly reduces the 
severity of clinical outcome and viral nasal shedding. The study in the Netherlands and Belgium 
showed that more severe outbreaks of EHV-1 occurred in unvaccinated equine populations 
compared to vaccinated (Goehring et al., 2006; Gryspeerdt et al., 2011). Moreover, to date, no 
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specific therapy is effective against EHV-1 infections (Garré et al., 2007). Thus, early 
institution of appropriate disease control measures such as isolation of clinically diseased 
equids, segregation and monitoring of exposed equids, and quarantine measures should be 
implemented to prevent and control the spread of the virus. At present, there is no EHV-1 
vaccine available in Ethiopia, and it is not clear to what extent the currently available vaccines 
may give protection for Ethiopian equids. Thus, more work is needed.  
 
Equine herpesviruses in Ethiopian equids with and without respiratory problems  
 
Respiratory pathogens are important causes of disease in equine populations worldwide. 
Previous studies have documented that respiratory problems, particularly coughing and nasal 
discharge are one of the major health concerns for working equids in Ethiopia (Laing et al., 
2016). Equine herpesviruses are important pathogens that are involved in respiratory problems 
of varying severity. However, information regarding their prevalence in equids with and 
without respiratory disease is not available in Ethiopia. Therefore, in chapter 3.2 of this thesis, 
we described the prevalence of EHV-1, -2, -4, and -5 and the genetic characterization of EHV-
2 and EHV-5 from equids with and without respiratory disease. In chapter 3.1, we already 
described the EHV-1-associated myeloencephalopathy outbreaks in Ethiopian equids. In this 
study, we also provide the molecular evidence of EHV-1, EHV-2, EHV-4, and EHV-5 infection 
in Ethiopian donkeys and horses with and without respiratory problems. We detected EHV-5 
at the highest prevalence (23.1%), followed by EHV-2 (20.0%), EHV-4 (8.1%), and EHV-1 
(7.5%) from 160 equids showing clinical signs of respiratory disease.  Of the total of 111 
clinically healthy equids, we detected EHV-2 and EHV-5 from 8 (7.2%) and 18 (16.2%) horses, 
respectively, while EHV-1 and EHV-4 were never detected. It has been reported in previous 
studies that EHV-2 and EHV-5 were detected from immunocompetent equids without signs of 
respiratory syndromes (Bell et al., 2006; Wang et al., 2007; Torfason et al., 2008). Thus, we 
supported the notion that the presence of EHV-2 and/or EHV-5 in equids is not sufficient to 
establish disease causality (Brault and MacLachlan, 2011), however, they may compromise 
host immunity and increase the susceptibility of the host to opportunistic infections 
(Nordengrahn et al., 1996; Dunowska et al., 2002). Furthermore, we recorded concurrent 
infections with EHV-2 and EHV-5 from 9 (5.2%) clinically respiratory diseased horses. In 
previous studies, simultaneous infection with EHV-2 and EHV-5 have been reported 
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(Nordengrahn et al., 2002; Back et al., 2009; Ataseven et al., 2010). We observed dual 
infections from horses only exhibiting clinical signs of respiratory disease, therefore, it is 
important to evaluate the synergistic pathogenic effect of these viruses on the respiratory tract. 
 
In this thesis, it was shown that both species of equids with respiratory clinical signs were 
infected with EHV-1, with a significantly higher prevalence in donkeys compared to horses. In 
chapter 3.1 of this thesis, a more severe clinical outcome and a larger proportion of donkeys 
infected with EHV-1 were reported, which indicated that the Ethiopian donkeys might be highly 
susceptible to EHV-1 infection. In contrast, we recorded a significantly higher prevalence of 
EHV-2 and EHV-5 in horses than in donkeys. It has been shown in previous studies that EHV-
2 and EHV-5 have predominantly been found in horses (Franchini et al., 1997; Craig et al., 
2005; Goehring, 2015). So far, information regarding infection of donkeys with either EHV-2 
or EHV-5 has not been reported. However, infection of the Przewalski’s wild horse and the 
mountain zebras with EHV-2 and EHV-5 were documented (Borchers et al., 1999). Thus, 
detection of EHV-2 and EHV-5 in donkeys is the first report, which provides an important 
contribution to a better understanding of the epidemiology of the disease. However, the varying 
level of susceptibility of donkeys and horses to EHV infections need to be further investigated.  
 
Although there has been an unequivocal evidence that the alphaherpesviruses EHV-1 and EHV-
4 are the major causes of respiratory disease in equids globally, the evidence that the 
gammaherpesviruses EHV-2 and EHV-5 as etiological agents of respiratory disease has not yet 
been defined. To this end, we compared the association of either EHV-2 or EHV-5 detection 
with the presence of respiratory clinical signs between equids displaying signs of respiratory 
disease and clinically healthy equids. In this study, we did not observe a significant difference 
in prevalence between EHV-5-infected equids in the respiratory diseased group and those not 
displaying signs of respiratory disease. Based on the presence of a high prevalence of EHV-5 
in clinically normal equids coupled with the absence of a significant variation between the 
respiratory diseased and clinically healthy equids, we strongly suggested that EHV-5 was 
unlikely to be involved in respiratory disease in equids. In contrast, we observed a significantly 
higher proportion of EHV-2-infected equids in the respiratory disease group compared to those 
without disease and the EHV-2-positive equids were three-times more likely to display clinical 
signs of respiratory disease than EHV-2-negative equids. This strong association and low level 
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of detection from clinically healthy equids proposed that EHV-2 could be involved as an 
etiological agent either to induce or predispose equids to respiratory diseases. However, further 
studies are needed to better understand the clinical outcome of EHV-2 and EHV-5 infections.  
 
In this thesis, we revealed a remarkable genetic diversity of the Ethiopian EHV-2 and EHV-5 
strains based on the phylogenetic analysis of the gB gene with the nucleotide sequence 
homology among each other and with other countries isolates acquired from GenBank. We 
found that a nucleotide sequence homology of Ethiopian EHV-2 strains among each other and 
with foreign EHV-2 strains ranged from 94.0 to 99.4% and 92.9 to 99.1%, respectively. 
Similarly, EHV-5 strains showed 95.1 to 100% and 95.1 to 99.5% nucleotide sequence 
homology among each other and with isolates from other countries retrieved from GenBank, 
respectively. This high degree of genetic heterogeneity in equine gammaherpesviruses EHV-2 
and EHV-5 have been reported in previous studies conducted elsewhere. Whether this genetic 
heterogeneity of the gammaherpesviruses has an association with the clinical outcome or not is 
not clear, thus, further investigation is needed.  
 
Invasion characteristics of EHV-1 in the nasal and vaginal mucosae 
 
Equids get the EHV-1 infection through inhalation of infectious aerosols or direct contact with 
infectious secretions. It is very well known that the respiratory mucosal epithelium is the 
primary site for EHV-1 replication. The virus breaches the basement membrane barriers by the 
use of infected mononuclear cells. Hereafter, the cell-associated viremia disseminates the virus 
to the target organs. Different strains of EHV-1 have a different pathological outcome, which 
is correlated with the variation in the ability to disseminate and establish infection in vascular 
endothelial cells of the target organs such as the endometrium, the central nervous system, or 
the eye (Patel et al., 1982; Hussey et al., 2013). It is essential to understand that different 
mucosal tissues are quite distinct in structural barriers, microenvironment, and the composition 
of available target cells. It was proposed that this unique characteristic of different mucosal 
tissues may dramatically influence the efficiency of EHV-1 replication. Several studies have 
been conducted on the replication kinetics and invasion mechanisms of EHV-1 in the equine 
respiratory mucosa. The replication efficiency in the vaginal mucosa was never studied before. 
The vaginal mucosa is the portal of entry for other alphaherpesviruses such as EHV-3 (Allen 
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and Umphenour, 2004), BoHV-1 (Bielanski et al., 2014; Wrathall et al., 2006), PRV (Romero 
et al., 2001) and CaHV-1 (Evermann et al., 2011). In previous studies, EHV-1 has been isolated 
from male genital organs (Tearle et al., 1996) and is shed with the semen and the sperm cells 
(Hebia-Fellah et al., 2009; Fritsche and Borchers, 2011; Walter et al., 2012). However, their 
transmission through the vaginal mucosa is not known, which could serve as an alternative 
portal of entry. Therefore, inspired by this knowledge, in chapter 4 of this thesis, we used a 
mucosa tissue culture system, that mimics the natural conditions, to compare and evaluate the 
replication kinetics and invasion behavior of the neuropathogenic and abortigenic strains of 
EHV-1 in the nasal and vaginal mucosal tissue. 
 
In this chapter, we demonstrated that EHV-l replicated and spread in a plaquewise manner in 
the epithelium and increases its size over time. We observed that EHV-1-infected mononuclear 
immune cells in the epithelium crossed the basement membrane and invaded the lamina propria 
of the respiratory and the vaginal mucosae. However, we noticed significantly different 
replication kinetics of EHV-1 in the nasal and vaginal mucosae, where both strains of EHV-1 
replicated better in the nasal mucosa compared to the vaginal mucosa as evaluated by the 
number of plaques counted, the size of the plaques, and the number of infected individual 
mononuclear immune cells. This suggests that the nasal mucosa is the primary tissue of 
preference for EHV-1 replication and entry into its host.  
 
Despite the fact that EHV-1 has a main tropism for the respiratory mucosa, the vaginal mucosa 
was able to support replication. In the vaginal mucosa, we observed a different magnitude of 
replication between the neuropathogenic and abortigenic strain. We clearly demonstrated that 
the neuropathogenic strain replicated less efficiently than the abortigenic strain and at 72h pi, 
we observed a lot of non-infected basal cells between the cluster of infected epithelial cells and 
the basement membrane for the neuropathogenic strain, but not for the abortigenic strain. The 
observed difference in replication efficiency between the two EHV-1 strains is associated with 
certain viral genetic factors. Goodman et al. (2007) reported that EHV-1 virulence and tissue 
tropism in the natural host are linked with the function of the DNA polymerase. Indeed, a single 
point mutation in this enzyme has been claimed to be responsible for the neurotropism. It is 
interesting to determine if this point mutation in this enzyme is also determining the level of 
EHV-1 replication in the vaginal mucosa.  
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In previous studies, the venereal shedding of EHV-1 from naturally infected stallions for three 
weeks was reported (Hebia-Fellah et al., 2009; Fritsche and Borchers, 2011; Walter et al., 
2012). Based on this information, a possible venereal transmission of EHV-1 may be proposed. 
Hitherto, the transmission of EHV-1 through the vaginal mucosa was largely unknown. With 
our ex vivo explant models, we provided an important new insight for the possible venereal 
transmission of the virus. Studies with other herpesviruses showed that the viral dose is an 
important factor determining for transmission through the vaginal mucosa. It was demonstrated 
that venereal transmission of BoHV-1 via artificial insemination can occur with a dose as low 
as 32 TCID50 in semen (Van Oirschot, 1995). Because the titer of EHV-1 shed with the semen 
has not been fully addressed, it is very important to determine this amount and evaluate its 
transmission either via artificial insemination or under natural conditions. 
 
The monocytic cells represent an important cellular target for EHV-1 during primary infection. 
We demonstrated a variable number of EHV-1-infected monocytic cells in the nasal and vaginal 
mucosal tissues. Although the vaginal mucosa has multiple layered epithelial cells with many 
resident immune cells, we observed a two-to-five-fold lower percentage of EHV-1-infected 
monocytic cells in the lamina propria of the vaginal mucosa compared to the nasal mucosa. 
Based on this data, we proposed the hypothesis that the vaginal microenvironment may provide 
an important role to reduce the number of cells hijacked by the virus. However, this needs to 
be further investigated. Monocytic lineage cells, which express surface marker CD172a, were 
the predominant cell type infected with EHV-1, followed by CD3+ T-lymphocytes independent 
of the strain and tissue. These monocytic cells serve as a “Trojan horse” to facilitate the 
dissemination of EHV-1 to target organs (Gryspeerdt et al., 2010; Vandekerckhove et al., 2010; 
Laval et al., 2015).  
 
Invasion characteristics of EHV-3 in the nasal and vaginal mucosae 
 
The alphaherpesvirus EHV-3 is the causal agent of equine coital exanthema, an acute venereal 
mucocutaneous disease of equids. EHV-3 is highly host specific and it replicates only in cell 
lines derived from equids (Allen and Umphenour, 2004; Barrandeguy et al., 2012). Although 
EHV-3 can establish genital and respiratory diseases, the underlying pathogenesis remains 
poorly understood. Therefore, in chapter 4 of this study, we used the nasal and vaginal mucosal 
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explant model to elucidate the replication kinetics and early event of invasion behavior of EHV-
3. Similar to EHV-1, we found a plaquewise manner replication characteristics of EHV-3. We 
observed the plaques in the epithelium starting from 24h pi and their sizes significantly 
increased over time. However, unlike EHV-1, we noticed restricted EHV-3 replication in both 
nasal and vaginal epithelial mucosae, where the virus neither breached the basement membrane 
to invade the lamina propria nor to infect individual mononuclear immune cells in all time 
points pi. This localized replication behavior might limit the EHV-3 dissemination via systemic 
blood circulation. Whether host factors or viral factors inhibit the virus to infect individual 
immune cells and to invade the underlying tissue is not clear and further investigation is 
recommended. Although both the nasal and vaginal mucosae can be infected with EHV-3, we 
observed a significantly strong replication in the vaginal mucosa than the nasal mucosa. This 
replication advantage of EHV-3 in the vaginal mucosa is associated with the clinical picture, as 
it causes vaginal lesions under natural conditions.  
 
General conclusions and future directions 
 
EHM is the most prevalent and devastating clinical outcome of the EHV-1-associated diseases 
in the Ethiopian equids. Donkeys and mules, besides horses, can be clinically affected by the 
neurological form of EHV-1. The neuropathogenic variant of EHV-1 is mainly responsible for 
the EHM outbreaks and all the EHV-1 isolates are allocated to geographical group 4. Because 
of the relatively fast course and fatal nature the EHV-1 infection in Ethiopian donkeys, future 
research should focus on elucidating the pathogenesis of EHM in donkeys using Ethiopian 
EHV-1 strains. In addition, the efficiency of EHV-1 vaccine has never been evaluated in 
donkeys and mules. Thus, it is important to evaluate the extent of protection using the currently 
available inactivated and live attenuated EHV-1 vaccines.  
 
Respiratory problems associated with EHV infections are a major concern for Ethiopian equids. 
Both equine alphaherpesviruses (EHV-1 and EHV-4) and gammaherpesviruses (EHV-2 and 
EHV-5) are common respiratory tract pathogens in Ethiopian donkeys and horses. EHV-1 and 
EHV-4 are detected only from equids with respiratory diseases, whereas EHV-2 and EHV-5 
are detected from both clinically ill and clinically healthy equids. In addition to EHV-1 and 
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EHV-4, EHV-2 is likely to be an important contributor either to induce or predispose equids to 
respiratory diseases.  
 
The vaginal mucosa is susceptible to EHV-1 infection, with the abortigenic strain replicating 
more efficiently than the neuropathogenic strain. EHV-1 can infect the mononuclear cells 
residing in mucosa and hijack these cells to invade the underlying connective tissue. The 
CD172a+ myeloid cells and CD3+ T-lymphocytes are the predominant cell types infected by 
EHV-1. Because of the vaginal mucosa and residing immune cells are infected with EHV-1, it 
is important to further evaluate its venereal transmission in vivo.  
  
EHV-3 replication is restricted to the epithelium of the nasal and vaginal mucosae and the virus 
neither breaches the basement membrane nor infect individual immune cells. EHV-3 replicates 
better in the genital mucosa than in the respiratory mucosa. 
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Summary  
 
The equine alphaherpesviruses (EHV-1, EHV-3, and EHV-4) and gammaherpesviruses 
(EHV-2 and EHV-5) are ubiquitous pathogens in equine populations worldwide. They 
establish a lifelong latent infection, which ensures the survival of herpesviruses in equine 
populations. The currently available modified live and inactivated products of EHV-1 and 
EHV-4 vaccines are not reliably providing protection against infection. A better 
understanding of the epidemiology of EHV infections in natural outbreaks is particularly 
important to formulate an effective intervention strategy. However, many data gaps exist 
and more investigation needs to be done. It is very well known that the respiratory mucosal 
epithelium is the primary site of EHV-1 replication. However, EHV-1 infection in the 
vaginal mucosa is largely unknown. Moreover, information regarding the pathogenesis of 
EHV-3 in the nasal and vaginal mucosa is limited. Therefore, this thesis aimed to describe 
the epidemiology of EHVs in Ethiopian equids and to elucidate early events of EHV-1 and 
EHV-3 invasion characteristics by the use of respiratory and vaginal mucosal explant 
system.  
 
In Chapter 1, an overview of the current knowledge of EHVs and the characteristics of the 
respiratory and genital mucosae were given. In this chapter, an introduction was given on 
the historical background, the taxonomy, the general herpesvirion structure, the replication 
cycle, the current understanding of the epidemiology, the pathogenesis and the EHV-
associated clinical signs. We also provided the general characteristics of upper respiratory 
and genital tract mucosal tissues with residing immune cells. 
 
In Chapter 2, the aims of this thesis were formulated. 
 
In Chapter 3.1, the epidemiology and molecular characteristics of EHV-1 from clinically 
EHM-affected Ethiopian equids during outbreaks from May 2011 to December 2013 were 
described. We recorded a higher incidence of EHM outbreaks from April to mid-June. There 
were no visible differences in the clinical presentation of EHM among horses, mules, and 
donkeys. However, EHM in donkeys was more severe and regularly death occurred after a 
short period of neurological signs. EHM-affected equids mainly observed over 3 years of 
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age and equids within the age ranged from 7 - 10 years (n = 51; 56.0%) were mostly affected. 
Further, we also documented that females were more affected than males. The incidence of 
neuropathogenic (D752) and non-neuropathogenic (N752) variants of EHV-1 from EHM-
affected Ethiopian equids was assessed by sequencing the DNA polymerase gene (ORF30) 
of the EHV-1 isolates. The results indicated that 98.9% (90 out of 91) equids were infected 
with an ORF30 D752 variant. Analysis of ORF68 as grouping marker for geographical 
differences showed that the Ethiopian EHV-1 isolates belonged to geographical group 4. 
Due to the fatal nature of EHV-1 in donkeys, it would be interesting to examine the 
pathogenesis of EHM in this species. At present, there is no vaccine available in Ethiopia, 
and therefore, outbreaks of EHV-1 should be controlled by proper management adaptations. 
In addition, it is important to test the efficacy of the commercial vaccines not only in horses 
but also in donkeys and mules.  
  
In Chapter 3.2, we described the detection and genetic characterization of EHVs from 
equids with and without clinical respiratory disease. Virus-specific PCRs were used to detect 
EHV-1, -2, -4, and -5. From the total of 160 equids with respiratory disease, EHV-5 was 
detected at the highest prevalence (23.1%), followed by EHV-2 (20.0%), EHV-4 (8.1%), 
and EHV-1 (7.5%). Concurrent infections with EHV-2 and EHV-5 were recorded from 9 
(5.2%) diseased horses. Of the total of 111 clinically healthy equids, EHV-1 and EHV-4 
were never detected whereas EHV-2 and EHV-5 were found in 8 (7.2%) and 18 (16.2%) 
horses, respectively. A significantly higher proportion of EHV-2-infected equids was 
observed in the respiratory disease group (32/160, 20.0%; P = 0.005) compared to those 
without disease (8/111; 7.2%). EHV-2-positive equids were three times more likely to 
display clinical signs of respiratory disease than EHV-2-negative equids (OR 3.22, 95% CI: 
1.42 to 7.28). For EHV-5, the observed difference was not significantly (P = 0.166) different. 
The phylogenetic analysis of the gB gene revealed that the Ethiopian EHV-2 and EHV-5 
strains had a remarkable genetic diversity, with a nucleotide sequence identity among each 
other that ranged from 94.0 to 99.4% and 95.1 to 100%, respectively. Moreover, the 
nucleotide sequence identity of EHV-2 and EHV-5 with isolates from other countries 
acquired from GenBank ranged from 92.9 to 99.1% and 95.1 to 99.5%, respectively. Our 
results suggest that besides EHV-1 and EHV-4, EHV-2 is likely to be an important 
contributor either to induce or predispose equids to respiratory disease. However, more work 
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is needed to better understand the contribution of EHV-2 in the establishment of respiratory 
disease. 
 
In Chapter 4, the replication kinetics and invasion characteristics of EHV-1 and EHV-3 in 
nasal and vaginal mucosae were compared using explants. The tissues were inoculated with 
EHV-1 03P37 (neuropathogenic), 97P70 (abortigenic), and EHV-3 04P57. The explants 
were collected at 0, 24, 48, and 72h pi, cryosections were made, fixed and stained for viral 
antigens by a double immunofluorescence labeling. The plaques were already observed at 
24 h pi, their size increased over time and did not directly cross the basement membrane. 
However, EHV-1 infected the monocytic cells and hijacked these cells to invade the lamina 
propria. In contrast, EHV-3 replication was fully restricted to epithelial cells; the virus did 
not breach the basement membrane via a direct cell-to-cell spread nor used infected 
monocytic cells. EHV-1-induced plaques were larger in the nasal mucosa compared to the 
vaginal mucosa. The opposite was found for EHV-3-induced plaques. Both EHV-1 strains 
replicated with comparable kinetics in the nasal mucosa. However, the extent of replication 
of the abortigenic strain in vaginal mucosa was significantly higher than that of the 
neuropathogenic strain. Two-to-five-fold lower numbers of EHV-1-infected monocytic cells 
underneath the BM were found in the vaginal mucosa than in the nasal mucosa. Our study 
has shown that (i) EHV-1 has developed in evolution a predisposition for respiratory mucosa 
and EHV-3 for vaginal mucosa, (ii) abortigenic EHV-1 replicates better in vaginal mucosa 
than neuropathogenic EHV-1 and (iii) EHV-3 demonstrated a strict epithelial tropism 
whereas EHV-1 in addition hijacked monocytic cells to invade the lamina propria. 
 
In Chapter 5, all data obtained in the present thesis were reviewed and discussed. A general 
conclusion on the research data generated in this thesis was formulated, in which the 
epidemiology of EHVs in Ethiopian equids and the new insights in the invasion behavior of 
EHV-1 and EHV-3 in the respiratory and vaginal mucosae were summarized. 
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De equine alfaherpesvirussen (EHV-1, EHV-3 en EHV-4) en gammaherpesvirussen (EHV-
2 en EHV-5) zijn alomtegenwoordig in paardenpopulaties wereldwijd. Ze veroorzaken een 
levenslange latente infectie waardoor het virus na de acute infectie aanwezig zal blijven in 
de gastheer. De beschikbare levende en geïnactiveerde EHV-1 producten en de EHV-4 
vaccins leiden niet tot een betrouwbare bescherming tegen infectie. Het beter begrijpen van 
de epidemiologie van EHV-infecties bij natuurlijke uitbraken is vooral belangrijk om een 
effectieve interventiestrategie te formuleren. Er zijn echter nog veel hiaten in de kennis 
hieromtrent en meer onderzoek dringt zich op. Het is gekend dat het respiratoire epitheel de 
primaire vermeerderingsplaats van EHV-1 is. Of EHV-1 ook de vaginale mucosa kan 
infecteren, is niet geweten. Verder is er weinig informatie over de replicatie-eigenschappen 
van EHV-3 in nasale en vaginale mucosae bekend. Het doel van deze thesis is daarom de 
epidemiologie van EHVs in Ethiopische paardachtigen te beschrijven en de vroege 
pathogenese van EHV-1 en EHV-3 infecties te verhelderen door gebruik te maken van 
respiratoire en vaginale mucosale explantsystemen. 
 
In Hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis van de EHVs en de 
karakteristieken van de respiratoire en vaginale slijmvliezen (mucosae). In dit hoofdstuk 
wordt een inleiding gegeven over de historische achtergrond, de taxonomie, de algemene 
herpesvirionstructuur, de vermeerderingscyclus, de huidige kennis van de epidemiologie, de 
pathogenese en symptomen van een EHV-infectie. We overlopen ook de algemene 
kenmerken van de slijmvliezen van de bovenste luchtwegen en de voortplantingsorganen 
met residentiële immuuncellen. 
 
In Hoofdstuk 2 worden de doelstellingen van de thesis uiteengezet.  
 
In Hoofdstuk 3.1 wordt de epidemiologie beschreven, alsook de genetische karakterisatie 
van EHV-1 van klinisch EHM-geïnfecteerde Ethiopische paardachtigen tijdens uitbraken 
van mei 2011 tot december 2013. We namen een hogere incidentie van EHM uitbraken waar 
van april tot half juni. Er waren geen zichtbare verschillen in de klinische presentatie van 
EHM tussen paarden, muilezels en ezels. Echter, EHM in ezels was ernstiger en frequent 
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werd sterfte zonder veel voorafgaande tekenen van paralyse waargenomen. EHM werd 
voornamelijk bevonden bij paardachtigen ouder dan 3 jaar en de overgrote meerderheid van 
de gevallen trof paarden tussen 7 en 10 jaar oud.  Verder hebben we ook gedocumenteerd 
dat merries vaker geïnfecteerd werden dan hengsten. De incidentie van neuropathogene 
(D752) en niet-neuropathogene (N752) varianten van EHV-1 van EHM-geïnfecteerde 
Ethiopische paardachtigen werd bepaald door sequentiebepaling van het DNA polymerase 
gen (ORF30) van de EHV-1 isolaten. De resultaten gaven aan dat 98,9% (90 van 91) van de 
paardachtigen werden geïnfecteerd met een D752 ORF30 variant. Analyse van ORF68 als 
groepsmerker voor geografische verschillen toonde aan dat de Ethiopische EHV-1 isolaten 
behoren tot de geografische groep 4.  Door de fatale aard van EHV-1 in ezels zou het 
interessant zijn om de pathogenese van EHM te onderzoeken in deze diersoort. Op dit 
moment is er geen vaccin beschikbaar in Ethiopië waardoor EHV-1 uitbraken enkel kunnen 
bestreden worden door aangepaste managementmaatregelen. Bovendien is het belangrijk om 
de werkzaamheid van de commerciële vaccins niet alleen bij paarden, maar ook bij ezels en 
muildieren te testen. 
 
In Hoofdstuk 3.2 beschrijven we de detectie en de genetische kenmerken van EHVs van 
paardachtigen met en zonder klinische respiratoire aandoeningen. Virus-specifieke PCRs 
werden gebruikt om EHV-1, -2, -4 en -5 te detecteren. Van het totaal van 160 paardachtigen 
met ademhalingsaandoeningen was de prevalentie het hoogst voor EHV-5 (23,1%), gevolgd 
door EHV-2 (20,0%), EHV-4 (8,1%) en EHV-1 (7,5%). Gelijktijdige infecties met EHV-2 
en EHV-5 werden waargenomen bij 9 (5,2%) zieke paarden. Bij de in totaal 111 klinisch 
gezonde paardachtigen werden EHV-1 en EHV-4 nooit gedetecteerd terwijl EHV-2 en 
EHV-5 werden gevonden bij 8 (7,2%) en 18 (16,2%) paarden, respectievelijk. Een 
significant groter aandeel van EHV-2 geïnfecteerde paardachtigen werd waargenomen bij 
de groep met ademhalingsstoornissen (32/160, 20,0%; P = 0,005) in vergelijking met dieren 
zonder ziekte (8/111; 7,2%). EHV-2-positieve paardachtigen hadden drie keer meer kans om 
symptomen van ziekte van de luchtwegen te ontwikkelen dan EHV-2-negatieve 
paardachtigen (OR 3,22, 95% CI: 1,42-7,28). Voor EHV-5 was het waargenomen verschil 
niet significant (p = 0,166) verschillend. De fylogenetische analyse van het gB gen bracht 
aan het licht dat de Ethiopische EHV-2 en EHV-5 stammen een opmerkelijke genetische 
diversiteit vertonen, met een overeenstemming in nucleotide sequentie die varieert van 
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respectievelijk 94,0 tot 99,4% en van 95,1 tot 100%. Bovendien varieerde de 
nucleotidesequentie overeenstemming van EHV-2 en EHV-5 met isolaten uit andere landen, 
verkregen van GenBank, van respectievelijk 92,9 tot 99,1% en van 95,1 tot 99,5%.  Onze 
resultaten suggereren dat naast EHV-1 en EHV-4, EHV-2 waarschijnlijk een belangrijke 
bijdrage levert aan het veroorzaken van ademhalingsziekte bij paardachtigen of 
paardachtigen vatbaarder maakt. Er is echter meer werk nodig om beter inzicht te krijgen in 
de bijdrage van EHV-2 in het veroorzaken van respiratoire aandoeningen.  
 
In Hoofdstuk 4 worden de kinetieken de invasiekenmerken van EHV-1 en EHV-3 in nasale 
en vaginale mucosae vergeleken met behulp van explanten. De weefsels werden 
geïnoculeerd met EHV-1 stammen 03P37 (neuropathogeen), 97P70 (abortigeen) en EHV-3 
stam 04P57. De explanten werden verzameld op 0, 24, 48 en 72 uur na infectie, en 
cryosecties werden gemaakt, gefixeerd en gekleurd voor virale antigenen met dubbele 
immunofluorescentiemarkering. De plaques werden reeds waargenomen vanaf 24 uur na 
infectie, hun omvang nam toe met de tijd en braken niet direct door de basale membraan. 
Echter, EHV-1 infecteerde monocytaire cellen en gebruikte deze cellen om de lamina propria 
te kunnen binnendringen. Daartegenover bleef de EHV-3 replicatie beperkt tot de 
epitheelcellen; het virus bracht geen schade toe aan de basaalemembraan via een directe cel-
cel spreiding noch gebruikte het virus monocytaire cellen om de basaalemembraan te 
penetreren. EHV-1-geïnduceerde plaques waren groter in het neusslijmvlies ten opzichte van 
die in het vaginale slijmvlies. Het tegenovergestelde werd gevonden voor EHV-3 
geïnduceerde plaques. Beide EHV-1 stammen vermeerderden even sterk in het 
neusslijmvlies. De omvang van vermeerdering van de abortigene stam in de vaginale mucosa 
was significant groter dan de vermeerdering van de neuropathogene stam. Het aantal EHV-
1-geïnfecteerde monocytaire cellen onder de basaal membraan was twee tot vijf maal lager 
in de vaginale mucosa dan in het neusslijmvlies. Ons onderzoek heeft aangetoond dat (i) 
EHV-1 in de evolutie een voorkeur voor de respiratoire mucosa ontwikkelde en EHV-3 voor 
de vaginale mucosa, (ii) de abortigene EHV-1 stam beter vermeerdert in het vaginale 
slijmvlies dan de neuropathogene EHV-1 stam en (iii) EHV-3 een strikte epitheliale 
voorkeur heft, terwijl EHV-1 ook gebruik maakt van monocytaire cellen om de lamina 
propria binnen te dringen. 
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In Hoofdstuk 5 worden alle verkregen gegevens in dit proefschrift beoordeeld en besproken. 
Algemene conclusie van de onderzoeksgegevens werd geformuleerd, waarin de 
epidemiologie van EHVs bij Ethiopische paardachtigen en de nieuwe inzichten in het 
invasieve gedrag van EHV-1 en EHV-3 in de luchtwegen en de vaginale slijmvliezen worden 
samengevat. 
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